A publication of { IDEC PHARMACEUTICALS Volume 2 Issue 1 3/02

一般

RECENT

 ZEVALIN'S APPROVAL BY THE FDA
 COMING DOWN THE PIPELINE

 building the cancer franchise
 renewing the spirit of IDEC




setting standards

Creating New Standards of Care is a core value at IDEC. We address this goal by striving to provide innovative, value-added therapies to treat cancers and autoimmune diseases—therapeutics like Rituxan® and Zevalin,[™] which offer treatment for patients with certain non-Hodgkin's lymphomas (NHL). But standard setting goes beyond product development at IDEC to reflect all aspects of our business. From research and development to manufacturing and sales, in our dealings with partners and contractors, and in our relationships with employees, shareholders, and the community, we challenge ourselves to meet —or even surpass—the highest goals.

1

6	Highlights of 2001
21	Ellen Cohen Award Winner
35	Selected Financial Data





A publication of **IDEC** Pharmaceuticals

William H. Rastetter, Ph.D. Chairman and Chief Executive Officer

William R. Rohn President and Chief Operating Officer

Paul C. Grint, M.D. Chief Medical Officer

Nabil Hanna, Ph.D. **Chief Scientific Officer**

Phillip M. Schneider **Chief Financial Officer**

Wolfgang Berthold, Ph.D. Senior Vice President, **Biopharmaceutical Sciences**

John M. Dunn Senior Vice President, Legal and Compliance, and General Counsel

Connie L. Matsui Senior Vice President, Planning and Resource Development

David F. Broad, Ph.D. Vice President, Biological Bulk Manufacturing

John Leonard, Ph.D. Vice President, Product Development

Edward M. Rodriguez Vice President, Finance and Controller

Christine A. White, M.D. Vice President, Medical Affairs

Michael E. Wiebe, Ph.D. Vice President, Quality

Mark Wiggins Vice President, Marketing and Business Development

Corporate Headquarters 3030 Callan Road San Diego, California 92121 Telephone: 858-431-8500 Facsimile: 858-431-8870

IDEC Pharmaceuticals®, PRIMATIZED® and Rituxan® are registered U.S. trademarks of the company. Zevalin™ and PROVAX™ are trademarks of the company.

© Copyright 2002 IDEC Pharmaceuticals.



2. Research and Development

We interview IDEC's chief medical officer, Dr. Paul Grint, about next generation yttrium-linked therapies, new approaches to cancer vaccines and surprising synergies between IDEC's cancer and autoimmune research programs.



Letter to Our Shareholders

of record growth.

IDEC's CEO, Bill Rastetter, reflects on

the company's fourth consecutive year



Building IDEC's Future

IDEC is preparing for its growth and future needs with the building of new manufacturing facilities and plans for a new corporate campus. With this activity has come a glimpse into California's geologic past.

≻ Standard Setters

IDEC's high standards are reflected in the quality of its employees as well as its products. The result is a diverse and dedicated workforce whose level of commitment is exceptional.



Setting New Standards

FDA approval for expanded

Rituxan[®] use and approval of

Zevalin[™] increase options for

standards for patient care.

NHL therapy, helping to set new

of Cancer Care

2

(911)

its fourth consecutive year of record growth in sales, revenues, profits, rowth over this extended period has been driven principally by Rituxan ncer by the U.S. Food and Drug Administration (FDA).

ones. The first occurred on March 21, when IDEC and Genentech, our n a cumulative basis since its approval by the FDA on November 27, 1997. Jucts and highlights the critical importance of this therapy in the lives of

ownturn in the U.S., IDEC reported U.S. net Rituxan sales of \$779 million J.S. sales in 2000. IDEC's annual revenues totaled \$272.7 million in 2001, million, or \$0.59 per share on a diluted basis in 2001, compared to net e period in 2000, despite an increase in our reported tax rate to 37 per-

apeutic regimen (ibritumomab tiuxetan), herein referred to as Zevalin, for B-cell non-Hodgkin's lymphoma, including patients with Rituxan-refracoval. This accomplishment is the fulfillment of more than a decade of hard four years ago, Zevalin's approval marks another important milestone in

ss, IDEC is committed to maintaining a robust pipeline of novel immunoveraging our knowledge, experience and leadership in antibody-based se II human clinical trials:

\$



Letter to Our Shareho IDEC's CEO, Bill Rastetter, the company's fourth cor of record growth.

20 Research and Development

We interview IDEC's chief medical officer, Dr. Paul Grint, about next generation yttrium-linked therapies, new approaches to cancer vaccines and surprising synergies between IDEC's cancer and autoimmune research programs.



(911)



Building IDEC's Future

IDEC is preparing for its gr future needs with the built manufacturing facilities ar new corporate campus. Wi has come a glimpse into C geologic past.

Standard Setters IDEC's high standards are in the quality of its employ its products. The result is a dedicated workforce whose mitment is exceptional. September 11th started out on a bright and promising note for IDEC Pharmaceuticals. At 8:00 a.m. in Bethesda, MD, an IDEC team began to give a presentation on the merits of Zevalin (ibritumomab tiuxetan), an investigational agent for the treatment of certain B-cell non-Hodgkin's lymphomas, to the 16-member Oncologic Drugs Advisory Committee. The panel was gathered to recommend to the U.S. Food and Drug Administration whether or not it should grant marketing approval of this therapy in the U.S. / At 8:46 a.m., the first of two passenger jets struck the Twin Towers. / In spite of the catastrophic events in New York, Pennsylvania and Washington, DC, the advisory panel persisted in its deliberations and ultimately did recommend approval of Zevalin to the FDA. The action prompted gratitude but not celebration among IDEC employees. We were too busy trying to make sense of the unfolding horror and cope with feelings of panic, fear and grief. This sense of precariousness lasted for weeks. / IDEC was touched directly on that dark day. We lost two good friends - Ed Pykon, 33, and Avnish Patel, 28, biotech analysts with Fred Alger Asset Management, Inc. Our hearts grieve for their loved ones and the thousands whose loved ones were taken from them on the worst day in American history.

arehold

A

DEAR SHAREHOLDERS: In 2001, IDEC Pharmaceuticals experienced its fourth consecutive year of record growth in sales, revenues, profits, cash balances, research and development investment and personnel. Our growth over this extended period has been driven principally by Rituxan (rituximab), the first monoclonal antibody approved for the treatment of cancer by the U.S. Food and Drug Administration (FDA).

RITUXAN SETS SALES RECORDS Last year Rituxan attained two major milestones. The first occurred on March 21, when IDEC and Genentech, our copromotion partner, achieved one billion dollars in U.S. net Rituxan sales on a cumulative basis since its approval by the FDA on November 27, 1997. This accomplishment places Rituxan in an elite group of cancer-fighting products and highlights the critical importance of this therapy in the lives of non-Hodgkin's lymphoma patients and their families.

The second milestone occurred at the end of 2001. Despite an economic downturn in the U.S., IDEC reported U.S. net Rituxan sales of \$779 million in 2001 with partner Genentech, a remarkable 84 percent increase over net U.S. sales in 2000. IDEC's annual revenues totaled \$272.7 million in 2001, a 76 percent gain over 2000. The company reported net income of \$101.7 million, or \$0.59 per share on a diluted basis in 2001, compared to net income of \$48.1 million, or \$0.30 per share on a diluted basis for the same period in 2000, despite an increase in our reported tax rate to 37 percent, compared to 17 percent last year.

ZEVALIN APPROVED On February 19, 2002, the FDA approved the Zevalin therapeutic regimen (ibritumomab tiuxetan), herein referred to as Zevalin, for the treatment of relapsed or refractory low-grade, follicular or transformed, B-cell non-Hodgkin's lymphoma, including patients with Rituxan-refractory follicular NHL. This is the first radioimmunotherapy to receive FDA approval. This accomplishment is the fulfillment of more than a decade of hard work by hundreds of IDEC employees and clinical investigators. Like Rituxan four years ago, Zevalin's approval marks another important milestone in the treatment of cancer and in the 15-year history of IDEC.

STRONG PIPELINE SUSTAINS GROWTH To sustain profitability and competitiveness, IDEC is committed to maintaining a robust pipeline of novel immunotherapies for the treatment of cancers and autoimmune diseases. By leveraging our knowledge, experience and leadership in antibody-based technologies, we currently have four therapeutic agents in Phase I and Phase II human clinical trials:

highlights of 2001

At the annual meeting of American Society of Hematology 24-month follow-up data from the Groupe d'Etude des Lymphomes de l'Adulte (GELA) Phase III study showed an increase in overall survival of 23 percent in patients with aggressive NHL treated with Rituxan and CHOP chemotherapy as compared to CHOP alone.

FDA Advisory Committee panel recommended approval of Zevalin for treatment of certain non-Hodgkin's lymphomas.

- IDEC-114 (anti-CD80 or anti-B7) Two Phase II clinical trials in psoriasis and a Phase I/II in NHL
- IDEC-131 (anti-CD40L or anti-CD154) One Phase II clinical trial in psoriasis, one Phase II clinical trial in immune thrombocytopenic purpura (ITP), one Phase II clinical trial in Crohn's disease, and one physician-sponsored IND in multiple sclerosis
- IDEC-151 (anti-CD4) A Phase II clinical trial in combination with methotrexate in rheumatoid arthritis
- IDEC-152 (anti-CD23) A Phase I/II clinical trial in allergic asthma.

We anticipate results from all Phase II clinical trials this year and will decide which therapeutic agents merit further development in Phase III clinical trials. In addition, we conducted preclinical research last year showing activity in animal models in NHL treated with IDEC-114 and Rituxan. In 2001 we began making preparations to launch clinical trials with IDEC-114 and initiated a Phase I/II trial in early 2002.

work is underway on the next generation of therapies Continual innovation and leadership are two hallmarks of a successful biotechnology company. In its 15-year history, IDEC has exemplified both traits—first with Rituxan and then with Zevalin, which is a first-in-class radioimmunotherapy.

IDEC will seek to maintain continual innovation and leadership by capitalizing on its core technologies through collaborations with the National Cancer Institute (NCI), academic centers and genomics companies for specialized technologies and skills.

For example, IDEC has been working on a "domain-deleted" antibody, which has certain fragments removed from its constant region through genetic engineering. When labeled with the yttrium-90 radioisotope, these domain-deleted antibodies may penetrate and deliver their yttrium-90 "payload" to solid tumors. In 2003, we hope to launch a pilot study with an yttrium-90-labeled, domain-deleted antibody, which, if successful, may lead to a variety of yttrium-based radioimmunotherapies for prostate, ovarian, colon and lung cancers.

IDEC also has been studying cancer vaccines for a number of years, especially in prostate cancer. We've devised a new technique for treating cancer by directing the patient's own immune system against specific tumor antigens, thus attacking the disease. Currently, we are combining prostatespecific PAGE-4 antigen with our PROVAX adjuvant in therapeutic vaccines in preparation for human clinical trials for the treatment of prostate cancer. In addition, IDEC has been examining preclinically the utility of IDEC-152 in chronic lymphocytic leukemia (CLL). IDEC-152 targets the CD23 recep-

2

1.1.1.1.4

4

910 A. W. H. H.

*

. -4

sharehold

fighting potential.

IDEC purchased site in San Diego for new corporate headquarters and research campus.

IDEC began Phase II study in psoriasis with its PRIMATIZED antibody, IDEC-114.

tor, which is expressed on CLL cells. Later this year, we hope to launch a Phase I/II clinical trial in CLL with IDEC-152 to study the therapy's cancer-WE ARE BUILDING FOR THE FUTURE Until recently, a biopharmaceutical company's fortunes rose or fell on the strength of its product pipeline. Today, bio-

pharmaceuticals need both a strong pipeline and the means to manufacture their therapeutic agents. Several dozen new biologics may be approved and launched in the next several years but, currently, capacity for manufacturing in our industry is scarce. Many biopharmaceutical companies with drugs in their pipeline are racing to build future manufacturing facilities to meet this critical shortfall. Over the past two years, we have been working to expand dramatically our biologics manufacturing capacity so that we may be "the architects of the future, not its victims," in the words of Buckminster Fuller. Currently, we have two major manufacturing projects in progress.

In 2001 the major portion of the 60-acre site in Oceanside, California, called NIMO (New IDEC Manufacturing Operation), was graded. This year, construction will begin on phase one, which includes approximately 450,000 square feet of facility space for manufacturing, warehousing, utilities, maintenance, laboratories and offices. We anticipate phase one to be mechanically complete in 2004, followed by commissioning and validation in 2005 and 2006. Meanwhile, IDEC purchased a 40,000-square-foot facility adjacent to NIMO. Called NICO (New IDEC Clinical Operation), it is expected to provide sufficient drug supply for our clinical trials, as well as drug supply for any potential drug launches prior to 2005. NICO should be equipped and in operation by 2003. In addition, IDEC purchased 42.6 acres for its new corporate headquarters and research and development campus. The new location is in San Diego and the campus could potentially expand to over 750,000 square feet of facilities. The first phase of construction is scheduled for completion in early 2004.

OUR PEOPLE MAKE THE DIFFERENCE In the future, when historians write the story of the first 100 years of the Biotechnology Century, they won't, if they're honest, focus exclusively on the scientific discoveries of a few of the industry's giants. Instead, the story will turn on the contributions of thousands of scientists in countless specialties, working anonymously at corporations, academic centers and government facilities, much like the thousands of largely unknown but passionate artists and artisans who ignited that cultural revolution we call the Renaissance.

If someone ever writes IDEC's history, their story will not focus on one or two individuals. Our story rests on the shoulders and lives in the hearts and minds of our dedicated employees. Through good times and bad, they have made the difference between success and failure, winning and losing. I urge you to turn to page 32 and read about four of them. Over the years we've been fortunate to recruit and retain employees who truly believe that "good enough" isn't good enough anymore to achieve leadership in our industry. They understand that leadership is attained and maintained only through "greatness," exemplified by first-in-class innovation, high quality standards and value-added therapeutic agents. These unyielding standards have allowed us to grow from a small nucleus of about two dozen employees in 1986 to 650 employees by the end of 2001. Emerson said, "The creation of the world is still in progress...at this very moment you're building tomorrow." I trust as you finish this letter you have a new awareness of our last year's accomplishments and a renewed confidence in our strategy for building IDEC's future.

In closing, I wish to express my heartfelt thanks to our dedicated employees, business partners, clinical investigators, doctors, nurses, patients and investors. Your support and encouragement over the past 15 years have dared us to be bold and resilient. Your long-term commitment has helped us discover, develop and commercialize new therapies for patients with cancer and autoimmune and inflammatory diseases. We look forward to what the next 15 years will bring to us all.

Best regards,

William H. Rastetter, Ph.D. Chairman and Chief Executive Officer, IDEC Pharmaceuticals Corporation

THE DISCUSSION OF OUR BUSINESS CONTAINED IN THIS ANNUAL REPORT MAY CONTAIN CERTAIN PROJECTIONS, ESTIMATES AND OTHER FORWARD-LOOKING STATEMENTS THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY. WHILE THIS OUTLOOK REPRESENTS MANAGEMENT'S CURRENT JUDGMENT ON THE FUTURE DIFECTION OF THE BUSINESS, THESE RISKS AND UNCERTAINTIES COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY. FOR A DISCUSSION OF CERTAIN RISKS AND UNCER-TAINTIES THAT MAY AFFECT OUR ACHIEVEMENT OF EVENTS IN THE FUTURE, PLEASE REFER TO OUR ANNUAL REPORT FOR THE YEAR ENDED DECEMBER 31, 2001, FILED WITH THE SECURITIES AND EXCHANGE COMMISSION OF FORM 10-K. AS WELL AS OTHER REPORTS ON FILE WITH THE SEC.

2

ON FEBRUARY 19, 2002, THE FDA APPROVED ZEVALİN (İBRİTUMOMAB TİUXETAN) FOR MAR-**KETING IN THE U.S. ZEVALIN IS INDICATED FOR** THE TREATMENT OF PATIENTS WITH RELAPSED FOLLICULAR. **OR REFRACTORY** TRANSFO DCKINS OR LYMPHOM/ ITS WITH RITUXAN FOLLIC-ULAR N NIDW CLASS LLED RADIO PIRIT-TICAG LITY OF A 11:10 POWE VELY DESTRO DAM-AGE TO FFERS AN IMP ARSE-NAL AGA TIENTS LONSE WHO NO STANDARD THERAPIES, AS DUCT THAT **IDEC WILL MARKET IN THE UNITED STATES** ON ITS **OWN. ZEVALÍN'S APPROVAL ALSO** SIGNIFIES IDEC'S EMERGENCE AS A FULLY **INTEGRATED BIOPHARMACEUTICAL COMPANY.**

1

3

Approved.

If someone over input and minds of our decom Lunge you to timn to ous "good enough "isn't por through "greathess," we have allowed us to group ation of the world is still our last year's accorptish In closing, I wish to e and investors. Your suppo us discover, development, the next 15 years with por

0

:

Best regards,

William H. Rastetter, Ph.D.

Chairman and Chief Executive Officer, IDEC Pharmaceuticals Corporation

THE COLORS OF BUILD AND ADDRESS CONTAINED IN THE ARGAIN AND ALL CONTACT ON ADDRESS TO PARTY AND ADDRESS AND ADDRESS TO ADDRESS TO ADDRESS AND ADDRESS

cated employees.

ves lighte hearts ning and losing, only believe that maligrained only reliding standards in said, "The crenew awareness of

nurses, patients

annward to what

ommitment has helped

ON FEBRUARY 19, 2002, THE FDA APPROVED ZEVALİN (İBRİTUMOMAB TİUXETAN) FOR MAR-**KETING IN THE U.S. ZEVALIN IS INDICATED FOR** THE TREATMENT OF PATIENTS WITH RELAPSED **OR REFRACTORY LOW-GRADE, FOLLICULAR. OR TRANSFORMED B-CELL NON-HODGKIN'S** LYMPHOMA (NHL) INCLUDING PATIENTS WITH **RITUXAN (RITUXIMAB) REFRACTORY FOLLIC-**ULAR NHL. ZEVALIN IS THE FIRST IN A NEW CLASS **nF** CANCER TREATMENTS CALED **RADIOIMMUNOTHERAPIES, SUCH THERAPEU-**TIC AGENTS COMBINE THE TARGETING ABILITY **MONOCLONAL ANTIBODY WITH** POWER OF A RADIOISOTOPE TO EFFECTIVELY **DESTROY TUMOR CELLS WHILE LIMITING DAM-**AGE TO HEALTHY TISSUES. ZEVALIN OFFERS AN IMPORTANT NEW THERAPY TO THE NAL AGAINST NHL, ESPECIALLY FOR PATIENTS WHO NO LONGER RESPOND TO STANDARD THERAPIES, AS THE FIRST PRODUCT THAT **IDEC WILL MARKET IN THE UNITED STATES OWN. ZEVALİN'S APPROVAL** İTS ALSO SIGNIFIES IDEC'S EMERGENCE AS A FULLY **INTEGRATED BIOPHARMACEUTICAL**

P H

1993

PH2

PH

1997-99

Approved

9




Jonathan Polikoff, M.D.

"HE WAS THRILLED WHEN I EXPLAINED THERE WAS AN ALTERNATIVE TO RESUMING CHEMOTHERAPY..."

11

Pete has several underlying illnesses in addition to his lymphoma and had suffered significant toxicity to the chemotherapy he received in 1997. Unfortunately he did not respond to Rituxan. He was thrilled when I explained there was an alternative to resuming chemotherapy. It's been 8 months now since he received Zevalin and he remains in remission and has been able to maintain his quality of life.



PATIENT:

Pete Vivoli

2/6/24

AGE: 78

TREATMENT DATE: 6/01 TIME IN REMISSION 8 months

Chemotherapy for non Hodgkin's lymphoma initially put former 18-year old civil engineer, Pete Vivoli, into remission. However, those treatments left him exhausted and affected his balance, making walking difficult After failing to respond sufficiently to Rituran alone, his oncologist gave Dete the opportunity in Summer 2001 to participate in clinical trials of an experimental regimen combining Rituran with Zevalin. Pete quickly responded to therapy with only mild infusion-related side effects, and experienced a total remission of his cancer As a result. Lete has resumed an active role in his church, set aside during bis illness, and once again enjoys daily walks and other activities.



Leo I. Gordon, M.D.

"ZEVALIN GIVES PATIENTS ANOTHER TREATMENT OPTION AFTER RITUXAN..."

E VOLUME 2 ISSUE I RUC

13

Zevalin gives patients another treatment option after Rituxan, other than repeated doses of potentially debilitating chemotherapy. We look forward to conducting further studies with this new radioimmunotherapy to determine how it will best fit into the overall treatment arsenal for lymphoma.



Laura Colton Tepper, a paralegal at a large national law firm, was first diagnosed with low-grade non-Flodghin's lymphoma in 1996 at the age of 40. While her physician tried two different chemotherapy regimens against Laura's disease, neither treatment produced a sustained response. The next participated in a clinical trial evaluating Rituxan against the experimental therapy Levalin. Enrolled in the Rituxan-only arm of the study, Laura's disease again responded but returned immediately on cessation of treatment. Finally, she was able to participate in a second clinical study of Levalin, where she received the radioimmunotherapy. She quickly responded to treatment and now remains disease-free after more than 3.5 years. Laura says that while she required several transfusions following her treatment with Levalin, her blood counts soon recovered and today she is enjoying a "whole new life."

CLINICIAN

Leo I. Gordon, M.D., Professor of Medicine, Northwestern University Medical School, Chicago, Illinois

PATIENT

Laura Colton Tepper

DOB: 8/27/55

AGE:

197

REATMENT DATE:

7/98 TIME IN REMISSIO

3.5 years



Warren Paroly, M.D.

"THIS CASE SHOWS PROMISE THAT PATIENTS WHO HAVE RELAPSED AFTER MULTIPLE CHEMOTHERAPIES MAY STILL RESPOND TO RITUXAN..." This case shows promise that patients who have relapsed after multiple chemotherapies may still respond to Rituxan. Clinical trials have confirmed that response to Rituxan may occur in patients independent of the results of chemotherapy.

Efficacy of Rituxan (rituximab) in the treatment of non-Hodgkin's lymphoms

Warren Paroly, M.D., North County Oncology Group, Oceanside, California

Dennis Markham

8/26/46

56

IME IN REMISSION

2/00 A lingering cold and small lump on his neck caused 56-year-old Southern California native, 18 months Dendis Markham, to see his doctor in early 2000. A bighsy of the lump resulted in a diagnosis of low-grade Mantle cell NHS. Juitially treated with CHOO chemotherapy, his lymph node tumors subsided. Unfortunately, Dennis had a difficult time enduring the side effects "the chemotherapy and his remission was short-lived. Four months later, a GI sean revealed that his camer had beturned. His ancologist then suggested treatment with Rituran. While he experienced a strong allergie-type response to this first Ritusian therapy, his adverse reaction was limited to the Alturan influence period. Moreover, he enjoyed a response to treatment lasting size months. When Dennis again began showing signs of his cancer's return, his oneologist suggested trying a maintenance regimen of once-a-month Alturian, which he has tolerated without adverse effects with the use of an autihistamine. Joday, Dennis has enjoyed a strong partial remission for over 1,8 months, with only two small abdominal tumors remaining stable. He says he is living every day the best that he can and once again is enjoying surfing and desert biking with his son and two daughters.

15

Now that Zevalin has been approved, IDEC will complete its transformation from a research and development organization to a biopharmaceutical company with a fully integrated commercial infrastructure. In recent months, the company has significantly grown its oncology sales force, adding 50 new sales representatives and managers to build a team of nearly 100 people. Each of these new hires has spent an average of 15 years in pharmaceutical sales including nine years of those focused on oncology. Added to IDEC's existing sales force, this group gives the company one of the most experienced oncology sales teams in the industry. • IDEC also added several new departments and functions to support the marketing and sales of Zevalin. These include product distribution and logistical support to help ensure that manufacturing, product kit assembly, ordering, packing, shipping and other supply activities meet forecasted demands. Employees in a new Medical Information department staff phone lines at IDEC to answer questions from doctors, nurses, pharmacists and patients about Zevalin's use and biological activity. These employees also support the efforts of investigators who are developing presentations and manuscripts that help to educate the medical community about current and potential future uses of Zevalin. A new Pharmacovigilance department oversees the documentation of adverse events about Zevalin reported to IDEC or in the medical literature, and makes reports to the FDA. Additionally, a Phase IV Clinical Trials group is already overseeing the efforts of investigators seeking to explore additional ways to use Zevalin. Their efforts include working with large investigator groups and others to help them develop trial protocols and meet FDA regulatory requirements for human clinical studies. • As a first-in-class therapy, Zevalin presents unique challenges both for its marketing and in coordinating its delivery to the patient. It is the first cancer treatment to involve both the community-based oncologist and the hospital-based nuclear medicine physician in its use. And, while the Zevalin regimen is complete in just eight days, the patient must visit the hospital several times during that period for treatment and imaging. IDEC is working closely with the medical community to build a team approach to using Zevalin. The physicians, the radiopharmacists who prepare Zevalin for use, the nuclear medical technicians who oversee administration and conduct patient scans, and the oncology and radiation nursing staffs who help administer treatment are all integral parts of that team—as are the patients. The company also plans to educate other members of the treatment team as well as patient groups, to familiarize them with the new therapeutic option. Additionally, IDEC has developed a kit for patient caregivers to assist family members through the treatment process. • Like Rituxan before it, Zevalin's approval by the FDA, is just the first step. IDEC is exploring new clinical trials with Zevalin in other types of lymphoma as well as chronic lymphocytic leukemia (CLL).

NOW THAT IDEC HAS RECEIVED MARKETING APPROVAL FOR ZEVALIN, ITS ADDITION TO THE TREATMENT ARSENAL FOR NHL BUILDS ON THE STANDARD OF CARE ESTAB-LISHED BY RITUXAN, ZEVALIN ADDS ANOTHER POWERFUL WEAPON-RADIATION-TO IDEC'S PORTFOLIO OF TARGETED IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER. THUS, THESE TWO AGENTS OFFER PATIENTS A VALUABLE NEW TREATMENT OPTION WHERE RITUXAN OR CHEMOTHERAPY ALONE IS NOT ENOUGH.

commercial product shipments to that market began in the third quarter of 2005. • Since its initial approval in late 1997, Rituxan has become a correctione of treatment for many patients with NHL. With partner Generatech, safet at this product have grown steadily, reaching \$779 million for 2001 an increase of 84 percent over last year. Surveys show that physiciant are using further more imquently. Clinical data reported in the metical literature and in peer-review meetings have supported the unatdwords of inneran in commission with chamotherapy. Updated results from the first clinical trial of Rituxan plus cyclophosphamide, doxorubi and the end-pretrisone (CH321-in Low-int) therapy still in remission after more that blood and bone marrow following treatment, the tents intermediate- and high-grade disease have been buried in follow-up, data from this trial show a 23 pA compared to CHOP alone. . IDEE and its bostport, Gong through a variety of clinical studies. These studies studies and Hodgkin's central nervous system by phonenas, clinical data also suggest a role for Ritugation the treatment Rituxan use, both alone and in combination with other drugs, i and rheumatoid arthritis.

ad all patients saw 60 percent of patients completing have marker of residual disease disappear from their pative textual marker. . Patients with more aggressive the known of the GELA trial. At a median of 24 months reressivicated, treated with Rituxan plus CHOP as to explore the full therapeutic potential of Rituxan sting post-mansplant lymphoproliferative disease the Most Intriguingly, however, preclinical and early thes and its mattners plan to increasingly explore time thrownocytopecter purpura (CIP), systemic lupus erythematosus

u ZZ D

á

budld the

NOW THAT IDTO HAS SECRIVED MARKETING EXPROVAL FOR ZEVALIN, ITS ADDITION TO THE TREATMENT ARSENAL FOR NEL BUILDS ON THE STANDARD OF CARE SETAR-LISHED BY SITULAN. ZEVALIN ANDS ANOTHER FOWERFUL WEAPON-HADIATION-TO IDEC'S FORTFOLIO OF TAMENTED INFOMPTICARESIES FOR THE THEATHTREAT OF CANCER. THUS, THESE TWO ASSNTS OFFER PATIENTS A VALUERLE NEW THEATMENT OFTION WHERE RITURN OR CHEMOTERIERS ALONE IS NOT ENOUGH.

le tar niz

to help ensure that monitoctoring, product life assertion. Madical information department start preventines at IDEC activity. These employees near support the efforts of levels by about current and potential future uses of Zevenin. A set on to IDEC on its the medical literature, and make the activity and the medical literature, and make the could and the endedual literature, and make the topological and endedication greatinements are and ing and the conditioning its active with the effort, et or the medicine physician in its are. And, which there is a set who prepare Zevelin insulate, the most sum at a set who prepare Zevelin insulate, the most sum at a whother any well as patient groups, to fair the set of the mentions through the traditional group.

normalization and protects shout Sevelle's use and binargical processionscripts blot help to esticate the medical dominanenergy and the events about Sevella reporttion is disardy overtheling the efforts of investition and the energy and the sevel of the sevel of the efforts of adverte events the develop that are reported observations to help them develop that are reported observations relations are the there are a seven and the efforts of the seven and the terms of the period at the effort of the protection and the terms of the period at the effort of the protection and the terms of the transmission are about the effort of the transmission are able of the effort of the transmission are able of the transmission and the terms of the transmission of the transmission and the protection of the transmission are able of the transmission and the terms of the transmission are able of the transmission and the terms of the transmission are able of the transmission and the terms of the transmission are able of the transmission and the terms of the transmission and the term of the transmission are shown and the terms of the transmission are able of the transmission are able to the terms of the transmission are able of the transmission are shown and the terms of the transmission are able of the terms of terms of terms of terms of the terms of the terms of

et forecaster demander Exceleneus in a new

\$424,2M

Rituxan also achieved new approval milestones during 2001, expanding its uses and spurring further market growth for this product. The FDA approved new product labeling, broadening Rituxan use in patients with relapsed or refractory, low-grade or follicular, CD20-positive B-cell non-Hodgkin's lymphoma to include multiple courses of therapy with the antibody. The agency also approved the use of up to eight, rather than four, weekly infusions and use of Rituxan in the treatment of bulky disease (tumors greater than 10 centimeters in diameter). • Rituxan also gained approval from the Japanese health authorities for the treatment of certain B-cell non-Hodgkin's lymphomas. Zenyaku Kogyo and Nippon Roche co-promote Rituxan in Japan, and commercial product shipments to that market began in the third quarter of 2001. • Since its initial approval in late 1997, Rituxan has become a cornerstone of treatment for many patients with NHL. With partner Genentech, sales of this product have grown steadily, reaching \$779 million for 2001, an increase of 84 percent over last year. Surveys show that physicians are using Rituxan more frequently. Clinical data reported in the medical literature and in peer-review meetings have supported the effectiveness of Rituxan in combination with chemotherapy. Updated results from the first clinical trial of Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in low-grade NHL patients saw 60 percent of patients completing therapy still in remission after more than four to seven years. Moreover, of seven patients who had a marker of residual disease disappear from their blood and bone marrow following treatment, six remain in complete remission and four remain negative for that marker. • Patients with more aggressive intermediate- and high-grade disease have been studied in a Phase III study conducted in Europe, known as the GELA trial. At a median of 24 months follow-up, data from this trial show a 23 percent improvement in overall survival in patients with aggressive NHL treated with Rituxan plus CHOP as compared to CHOP alone. • IDEC and its partners, Genentech and F. Hoffmann-LaRoche Ltd., continue to explore the full therapeutic potential of Rituxan through a variety of clinical studies. These include studies with Rituxan in other B-cell malignancies, including post-transplant lymphoproliferative disease and Hodgkin's central nervous system lymphomas, as well as chronic lymphocytic leukemia (CLL). Most intriguingly, however, preclinical and early clinical data also suggest a role for Rituxan in the treatment of autoimmune and inflammatory diseases. IDEC and its partners plan to increasingly explore Rituxan use, both alone and in combination with other drugs, in the treatment of immune thrombocytopenic purpura (ITP), systemic lupus erythematosus and rheumatoid arthritis.

\$152.1M

0

~

interview

ROHN HAS BEEN IDEC'S CHIEF OPERATING OFFICER SINCE 1998. IN JANUARY 2002, HE ALSO BECAME COMPANY'S PRESIDENT IN RECOGNITION OF HIS ROLE IN ESTABLISHING AND BUILDING RITUXAN A BLOCKBUSTER THERAPEUTIC AGENT FOR CERTAIN B-CELL NHLS AND HIS LEADERSHIP IN MAKING IDEC A SUCCESSFUL, COMMERCIAL ENTERPRISE.

1

How have Rituxan sales grown since the product was approved in late 1997? Sales have experienced a dramatic increase since product launch, growing from \$152 million during the first full year of commercialization to \$779 million for 2001. In the latest year alone, we experienced an 84 percent increase over the prior year. That is an extremely high rate of growth for a product now in its fifth full year of commercialization.

2

Have you and others continued to study Rituxan? Absolutely. Right from the beginning we have encouraged and actively supported a broad range of Rituxan clinical experiments. Since approval, IDEC and its partners have conducted or supported well over 150 clinical trials around the world. As an example of the productivity of this effort I would point to the more than 90 scientific presentations and posters on Rituxan at the American Society of Hematology meeting in 2001.

3

Do you expect Rituxan use to continue to increase going forward? We are very excited about the additional market potential that exists for this product. The GELA trial, which studied Rituxan use in combination with CHOP chemotherapy in patients with more aggressive lymphomas, has shown this combination regimen can significantly increase event-free survival. Clinical investigation of Rituxan maintenance therapy is also underway. Success in this area, where we begin to treat lymphoma as a chronic disease rather than one requiring only acute intervention, could further spur sales growth. We are also excited about studies that suggest Rituxan may have potential in a variety of other malignancies, like chronic lymphocytic leukemia, as well as non-malignant diseases like immune thrombocytopenic purpura (ITP), hemolytic anemia, and even rheumatoid arthritis.

4

Are international sales of Rituxan growing as well? Acceptance of Rituxan

(also known as MabThera outside of the United States and Japan) was initially slower than in this country. However, sales by our marketing partner, F. Hoffman-LaRoche Ltd., have increased very dramatically in the past year, driven by the results from the GELA study. Additionally, we received approval for Rituxan in Japan in June 2001, where it is now co-promoted by Zenyaku Kogyo and Nippon Roche. The main countries accounting for 50 percent of ex-U.S. sales are: Germany, France, Italy, Japan and Australia.



In January 2001, Paul Grint, M.D., joined IDEC as chief medical officer and senior vice president of clinical research and development. Dr. Grint discusses IDEC's research pipeline and synergies between the company's programs in cancer and autoimmune disease. • Zevalin is the first radioimmunotherapy to achieve approval for cancer. What are IDEC's plans for developing other Yttrium-based cancer products? No We are currently conducting preclinical studies and are collaborating with others on a pilot clinical trial with certain "domaindeleted" antibodies labeled with Yttrium. These are engineered antibodies whose small size may enable them to better penetrate and kill solid tumors which are not easily treated with whole antibody approaches. Positive results from this research could open the door to development of a range of Yttrium-based radioimmunotherapies for such diseases as prostate, ovarian, colon



2001, the inaugural award honored Wendy (arpham, M.D., lymphoma survivor and note thor on cancer survivorship, whose four books hat left numerous patients and their families cope with

Ellen Glesby Cohen Leadership Award recogni anding contributions by an individual to Jy na research or the lymphoma community. In t ient's honot, IDEC presents a \$25,000 resear t to the Lymphoma Research Foundation.

* 2001 *

vill IDEC choose targets for cts? A>> IDEC has instituted an to identify antigens that are in these cancers. We have database of genes expressed sues that we are mining for 1, we have teamed with two tify genes over-expressed in iants of antigens associated cancer antigens discovered e useful as antibody targets ines. 🛯 Are you working on Ve are developing vaccine apy based on our patented y. Currently, we are combinantigen with our **PROVAX** ccines for prostate cancer.

In January 2001, Paul Grint medical officer and senior research and development. research pipeline and syner programs in cancer and aut is the first radioimmunother cancer. What are IDEC's Yttrium-based cancer produ ducting preclinical studies others on a pilot clinica deleted" antibodies labele engineered antibodies who them to better penetrate and k easily treated with whole an results from this research co opment of a range of Y therapies for such diseases

🛞 THE WINNER 🐰

As a former internist and longterm survivor of NHL, Dr. Wendy Harpham has a unique perspective on cancer and its effects on people's lives. When Dr. Harpham's illness prevented her from active clinical practice, her own experiences motivated her to help others deal with the many physical and emotional issues posed by cancer and its aftereffects. Today she lives a full life as an award-winning author and nationally recognized speaker who helps inspire cancer survivors and their families, as well as the physicians, nurses and other professionals who care for them.



Dr. Harpham's first two books, "Diagnosis: Cancer," and "After Cancer: A Guide to Your New Life" provide reader-friendly guides for patients undergoing cancer therapy and dealing with the medical, emotional and practical issues that can arise for years afterward. A third book, "When a Parent Has Cancer: A Guide to Caring for Your Children," with its companion children's book, "Becky and the Worry Cup," help families give children the tools to cope and grow in the setting of a parent with cancer. Similarly, a new book, "The Hope Tree," co-written with children's author Laura Numeroff, helps families talk about the difficulties that children face when one of their parents has cancer.

IDEC 2001 ANNUAL REPORT

CARE • VOLUME

and lung cancers. . How will IDEC choose targets for these new anti-cancer products? IN IDEC has instituted an in-house discovery program to identify antigens that are selectively over-expressed in these cancers. We have also licensed a commercial database of genes expressed in cancerous and normal tissues that we are mining for potential targets. In addition, we have teamed with two genomics companies to identify genes over-expressed in colon cancer and unique variants of antigens associated with other tumor types. The cancer antigens discovered through these efforts may be useful as antibody targets or for creating cancer vaccines. • Are you working on any cancer vaccines? _{A>} We are developing vaccine approaches to cancer therapy based on our patented **PROVAX** adjuvant technology. Currently, we are combining prostate-specific PAGE antigen with our PROVAX adjuvant in therapeutic vaccines for prostate cancer.

D>> IDEC is also developing a portfolio of other antibodies that intervene in key immune system events. The company has been investigating these for use in autoimmune and inflammatory diseases, but might they have additional uses in cancer? A>> Yes, preclinical research suggests a role for several of these antibodies in cancer. For example, IDEC-114 has demonstrated in laboratory and animal studies the ability to kill lymphoma cells on its own. When we combine this antibody with Rituxan, we see an enhanced anti-cancer activity in these preclinical models. Based on these observations, we began a clinical program to study IDEC-114 in patients with NHL in December 2001 and began a Phase I/II in early 2002. ()>> Do any of your other investigational antibodies show potential in cancer? A>> We are currently conducting preclinical studies of IDEC-152 in chronic lymphocytic leukemia (CLL). The CD23 receptor targeted by these antibodies appears in large quantities on CLL cells, and so appears to be a good target for this disease. We have shown that IDEC-152 can, on its own, trigger programmed cell death, or apoptosis, in cells taken from patients with CLL. Moreover, combining IDEC-152 with Rituxan appears to enhance that antibody's cancer-killing potential. 0>> We understand that Rituxan may also find new uses in the field of autoimmune disease? A> Yes, early clinical studies sponsored by F. Hoffmann-LaRoche suggest that Rituxan may be useful for the treatment of rheumatoid arthritis. Similarly, early data from studies of Rituxan in the treatment of immune thrombocytopenic purpura suggest it may be useful in this disease.

IDEC-114 (anti-CD80 or anti-B7) This PRIMATIZED® antibody inhibits the binding of the B7-1 ligand on antigen-presenting cells to the CD28 receptor on T cells, thus blocking inflammatory T-cell activation. Inappropriately activated T cells play a central role in many autoimmune disorders, making IDEC-114 potentially useful in a variety of diseases. Phase II studies in moderate to severe psoriasis are ongoing where B7 is expressed on activated T cells in skin lesions.

IDEC-131 (anti-CD40L or anti-CD154) This humanized antibody targets the CD40 ligand on T cells, which interacts with antibodyproducing B cells. By regulating this interaction, IDEC-131 may reduce excessive antibody production and help restore a more normal immune response in patients with autoimmune conditions. Phase II trials are ongoing in patients with Crohn's disease, moderate to severe psoriasis, and idiopathic thrombocytopenic purpura, an autoimmune blood-clotting disorder.

IDEC-151 (anti-CD4) This PRIMATIZED

antibody binds to the CD4 receptor on helper T cells, which direct the immune response. By blocking T-cell activation without seriously affecting other immune functions, IDEC-151 may provide a longer-acting and potentially less toxic alternative to current treatments for inflammatory diseases. A Phase II trial of IDEC-151 in combination with methotrexate is ongoing in rheumatoid arthritis.

IDEC-152 (anti-CD23) By binding to the CD23 receptor on B cells, PRIMATIZED IDEC-152 selectively regulates production of IgE and inhibits inflammation. Results of a Phase I study in patients with allergic asthma produced substantial reductions in IgE levels along with an acceptable safety profile, and IDEC recently began a Phase I/II study in this indication.

IDEC 200I ANNUAL REPORT

ISSUE

5

V O L U M E

IDEC 114	(psoriasis and NHL)			•
IDEC 131	(psoriasis, ITP, and other in	edications)		•
IDEC 151	(rheumatoid arthritis)			•
IDEC 152	(allergic asthma)		•	

D>> IDEC is also developing a portfolio of other antibodies that intervene in key immune system events. The company has been investigating these for use in autoimmune and inflammatory diseases, but might they have additional uses in cancer? A> Yes, preclinical research suggests a role for several of these antibodies in cancer. For example, IDEC-114 has demonstrated in laboratory and animal studies the ability to kill lymphoma cells on its own. When we combine this antibody with Rituxan, we see an enhanced anti-cancer activity in these preclinical models. Based on these observations, we began a clinical program to study IDEC-114 in patients with NHL in December 2001 and began a Phase I/II in early 2002. ()>> Do any of your other investigational antibodies show potential in cancer? A>> We are currently conducting preclinical studies of IDEC-152 in chronic lymphocytic leukemia (CLL). The CD23 receptor targeted by these antibodies appears in large quantities on CLL cells, and so appears to be a good target for this disease. We have shown that IDEC-152 can, on its own, trigger programmed cell death, or apoptosis, in cells taken from patients with CLL. Moreover, combining IDEC-152 with Rituxan appears to enhance that antibody's cancer-killing potential. 0>> We understand that Rituxan may also find new uses in the field of autoimmune disease? A>> Yes, early clinical studies sponsored by F. Hoffmann-LaRoche suggest that Rituxan may be useful for the treatment of rheumatoid arthritis. Similarly, early data from studies of Rituxan in the treatment of immune thrombocytopenic purpura suggest it may be useful in this disease.

υ

ISSUE

6

V O L U M E

Common elements exist between IDEC's research in blood-based cancers like lymphoma and our efforts in autoimmune and inflammatory diseases. Both involve immune system cells — T cells and B cells — and the particular receptor targets expressed on their surfaces. We find that Rituxan shows potential for treating certain autoimmune illnesses. Likewise, certain of our antibody treatments for autoimmune and inflammatory diseases may offer new weapons against lymphomas and leukemias.

		3
	•	
	•	
	•	
•		

ESTIMATED COMPLETION

. ІДЕС НО 2006

I I MO

(2004)

IDEC began constructing its future in earnest during 2001. The company achieved key milestones with respect to its planned New IDEC Manufacturing Operation (NIMO) in northern San Diego County. IDEC also began work on an adjacent facility aimed at supporting product needs for clinical trials. In addition, the company initiated plans to build a new corporate campus to accommodate IDEC's continued growth.

NICO While planning NIMO, IDEC realized that its current manufacturing facilities would soon be insufficient for supplying all of the drugs needed for the company's clinical trials. As a result, the company purchased in April a large building adjacent to the NIMO site. There, IDEC is creating a new facility for the manufacture of clinical supplies and, potentially, product launch material. The company aims to complete construction of

this new facility by the end of 2002 and to be in full production there by late 2003.

NIMO Work on NIMO advanced

WITH SUCCESS COMES GROWTH. IDEC EXPECTS TO DOUBLE ITS EMPLOYEE NUM-BERS OVER THE NEXT FEW YEARS. IN ANTICIPATION, THE COMPANY BEGAN PLANNING FOR FUTURE NEEDS WITH THE PURCHASE OF 42.6 ACRES NEAR SAN DIEGO'S UNIVERSITY TOWNE CENTRE. HERE, NOT FAR FROM IDEC'S CURRENT HOME, THE COMPANY IS BUILDING ITS NEW HEADQUARTERS, WHICH IS SCHEDULED FOR COMPLETION IN THE FIRST HALF OF 2004. PHASE I OF THIS PROJECT, ENCOM-PASSING OVER 300,000 SQUARE FEET OF OFFICE AND



LABORATORY SPACE, WILL HOUSE THE COMPANY'S RESEARCH, DEVELOPMENT, AND ADMINISTRATIVE STAFF.

steadily throughout 2001. IDEC chose key contractors for design and

construction of the planned facility, which is expected to provide 21 times the manufacturing capacity of IDEC's current operations. The company also completed two important computer models of NIMO. The first, an architectural rendering, lets the viewer examine the building design in three dimensions. The second is a dynamic model that encompasses all of the tanks and piping, including clean steam systems planned for NIMO. Using this model, IDEC can conduct a "virtual" manufacturing process to understand how well the system works within a given structural configuration before it is actually built.

In early 2001, construction activities on the site of IDEC's planned NIMO facility in Oceanside, California exposed fossil deposits from the Eocene age, about 42 to 45 million years ago. Members of the Paleontology Department of the San Diego Natural History Museum collected a number of specimens from the site, including remains of large land mammals. The scientists also found older marine deposits containing a variety of fish and other sea creatures, 45 to 47

million years

12.000.000 W. Bustehm >

old.

ExtENIOR UTLITY ECHCENE ADDRESS DUCTOR

DRADING OF SITE.

RIVER PLACE PLACE EXPERITE.

of 7-resider Starface

111/11/2/2011/11/22

W. So by Lett

Manife arrents

\$2-\$F,000,000 \$C

In early 2001, construction activities on the site of IDEC's planned NIMO facility in Oceanside, California exposed fossil deposits from the Eccene age, about 42 to 45 million years ago. Members of the Paleontology Department of the San Diego Natural History Museum collected a numand stated berget specimens from the site, WAGMOD HAT HOLTANDITHA HI STATE LUGING REVIE MAINS OF ALLAR OF 42 & ACRES NEAR SAN DIEGO'S WINVERSITY TOWNE DETTINE HERE found older IOT FAR FROM IDEC'S CURRENT ROME THE COMPANY IS BOA DOID -niaino site deposits contain-MODY TOTOLES SHE SET SEAHS HOUS TO SUAN LING WAT LET & VATIETY OF Fish -BOR STAR AN THE SALARS OF AND SALASSING OLDER SEE CTERtures, 45 to 47 LEBORAVORY SPACE WILL HOUSE THE COMPANY'S RESEARCH, DEVELOPMENT (HE ADMINISTRATIVE STAFF. million vears

minimif an oncours


NIMO work on NDB forced the design and the method work of NDB could be could be contracted on the design and mistaxed word the planned former of the contracted to model the method of the comparation councils of NEC's element operations. The compare active coupleted two forces are compared on ADMO. The WHI, an architectural rendering, lists the story of the DC futtering design in the domain a contract of ADMO. The WHI, and architectural rendering, into the story of the DC futtering design in the domain a contract of ADMO. The WHI, and architectural rendering, and the story of the DC futtering design in the domain a contract of the dynamic model that encomparate all of the tanks and plants indeding clean them systems the bound of the dynamic model. IDEC can consider a furrual manual facturing process to understand how which a the large thin a given structural configuration before it is actually with.

TROPOSE AND A CONTRACT OF A CONTRACTACT OF A CONTRACT OF A CONTRACT OF A CONTRACT OF A CONTRACT OF A

INDER THE

CONTRACTOR AND AND

#3112-T11944



urn, Karen Atkinson, Michael Bacica, Matthew Bacis, Michelle Bailey, Tisha Baird, Ben Bakerink, Phyllis Balan, Mark Baldwin, Edgar Ballesteros, Edwa	ard Ballesteros, Lionel Barboza, Denise B itt, Donna Barnett, Sandra Barton, Thomas Basinski, Walter Bateman, Bruce Batson, Mark Baum, Matthew Beaulieu, Laurie Beczkowski, Joanna Behler, Julia Benedetti, Rita Bergers, Lisa Berquist,
ann Ratthold Christina Bavilarnua. Carolin Ravis Kathlaan Rinalow, Hourk Augustus Rilly Christonhar Rimia. Lisat Rlanco. Pamala Rlas. Arthur Rlun	m Diana Bork Shawn Bohannan Bruaman 🔪 🔥 orth Bradford Borlen Christopher Bork Frie Romath Bord Hannah Brad Hannah H
	1
da Brokhausen, Tobin Brosnahan, Sara Brown, Steven Buchholz, Carl Bullen, Christopher Burman, Laura Burness, James Burnham, Brenda Burtnett,	Rudolph Bustamante, Barton Butler, Douglas Cababa, Yolanda Cabarloc, Susan Cairelli, Bryant Cameron, John Campbell, Carol Candiano, Jeffrey Cannon, Xianjun Cao, Antonio Carion, William Carisle, Carol Carlson, Samuel Carnibucci, Matthew Carpenter,
Carrier, David Carrillo, Cathleen Carter, Susan Cassidy, Thomas Cavaretta, Augusta Cerny, Radhika Chalam, Gary Chambers, Randall Champagne, Yu-Hsia	iang Chang, Shahbaz Chaudhary, Henry Che, Yeou Chen, Nicole Chieffo, Leyda Ching, Paul Chinn, Charmie Chirgwin, Yongjoon Cho, Douglas Christian, Peter Chu, Maureen Gielo, Jimmy Grelli, Janet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco
Pathara Compose Juan Contae Prian Connare Donnie Coones Mark Cristopal Timothy Crowley Frie Cunningham Damian Cunningham Dobost Cutto	her Folgen Freiles Behre Behi Andren Been Heit Breiten Bedrein Mehrin Bedrein Mehrin Behren Beitre Beite Freintenber Betren Behrenn Behrenne Behr
, balbara compeau, gynn conreg, orian connors, bennis cooneg, mark criscobal, riniocrig crowcey, circ canningnam, bannan canningnam, nobert caue	en canten capa, baian bain, minien baing, man baineto, mana baineto, menin baris, cin baris, cin baris, baian bain, minien baing, man baineto, mana baineto, mana baineto, mana baineto, mana baineto, mana baineto, mana baineto, mana baineto, mana baineto, mana baineto, mana baineto, mana
er, Allan Delacruz, Hugo Delgadillo, Charles Demeree, Frederick Denning, Berg Derderian, Daniel Derwin, Anne Dexheimer, Reynaldo Dimagiba, Jr., G	George Dimitrov, Peng Ding, Rosa Dix, Jemelle Dizon-Maspat, Michael Donovan, Susan Dowden, Mandana Dowlat, Paul Draper, Marie Drum, Bonnie Duggan, Robert Dunn, John Dunn, Todd Edgington, Mikel Edwards, Emelym Eldredge, Amr Elkhayat, Cynthia
ton, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Glenn England, Wendy Erler, Robert Ernst, Mark Erwin, Frank Escarcega, Michael Espanol, S	Susan Estrada, Maria Estrella, James Fabio, Julie Fair, Michael Fairchild, Eric Fallon, Qian Nancy Fan, Mark Farmer, Abraham Fausto, Michael Favis, Chad Feiler, Stuart Feinzig, Kimberly Fields, Susette Fino, Jonathan Fitchett, Kenneth Fite, Edith Fite, Joyce
ng, Geraldine Fontillas, Sharlene Forbes, Helen Forrester, Lisa Fox, Christopher Frame, Luis Franco, Jr., Anthonia Freeman, Chester French, Dennis Fri	rieele, Christian Friese, Ellen Fujikawa, Ala Gaidasz, Carol Gallagher, Denise Garcia, Marisa Gard, Paul Garza, Isabelle Gaston, Dennis Gately, Kristina Gaus, Moniza Gaya, Michelle Gegwich, Aikaterini Gekas, Larry George, Anthony Gerran, Swarnalata Ghanta,
Giambrone, Jack Giese, Catherine Gilbody, Judith Giri, Leonard Giuliano, Edward Glover, Aaron Godwin, Ann Gonzales, Rosie Gonzalez, Lisa Gordon,	Gregory Gorgas, Richard Graham, Andrew Grant, Dylan Grant, Amanda Grasis, Marcia Gray, Judith Gray, Paul Grint, Gui-Rong Guo, Brandy Gustafson, Juan Gutierrez, Joseph Ha, Jill Hacker, Dennis Hallissey, Leslie Halsey, Kenneth Hamilton, Nabil Hanna,
Unean Kandaramu Datharan Steine Darter Janathan Datley Karen Datesuau Patrick Dauet Suran Daure Valenties Daurhi Cheed Dered Jac	renk Heldmann Tr. Mannet Helm Fellers Handwerne Benich Hanke Kau Hanninger Mahel Hannanders Beilin Harnen Belansk Hanker, Terenk Harr Fel Licke Berin Hild Sama Hill Terenk Hell Ankon
напзоп, капиазанку напнанан, эселен нагнез, зопаснан нагсеу, катен наснамаў, гаспок насірс, зозан насзе, часенсна науазні, спетус неако, зоз	зери нешивали, эк, мандок нели, некка неписерон, закла неписе, кау непиларе, нача непалие, эке непалие, нача непание, зака непание непание непание непание непание непание непание непание
Ryan Hirschon, Carl Hixon, Hanh ThiHoang, Michael Hoar, Elaine Hom, Jennifer Hopp, Charles Howe, Veronica Howell, Susan Howerton, Patrick Hoy, F	Rong-Fong Huang, Yao-ming Huang, Ruben Huerta, Christian Hughes, Richard Hughes, Steven Humsicker, Matthew Hunt, Suzanne Hunt, Lynne Hunt, Leon Hyatt, Teody Ignacio, Shino Inouye, Jesse Ivers, III, John Jacanin, Peter James, Douglas Jankowski,
anson, Kristine Jaramillo, Greer Jattan, Amha Jember, Living Jiang, Jeffrey Johnson, Shawn Johnson, Vanessa Johnson, Robert Johnson, Pascale Jo	nnes, John Jaroensen, Ramon Juarez, Jaeho Jung, Andrea Kalinowski, Mue Kani, Laurence Kaplan, Wesley Karch, Nadezhda Katkova, Barbara Katz, Timothy Kazules, Marilyn Kehry, Steven Kelly, Steven Kedall, Kristine Kepler, Janice Kern, Daniel Kim, Yune
Martin King, Timothy Kirchner, Terry Klinker, William Kloetzer, Denise Knight, Hayden Knox, Kenneth Knox, Joanne Kolman, Laurel Konkol, Kathleen	Konrad, Mark Koozer, Christine Kopelev, Be-Sheng Kuo, Michael LaBarre, Renee Lamb, Jamie Lamb, Jordan Lambrecht, Richard Landin, Elizabeth Lara, Ronald LaRoux, Leilani Larson, Geofe Lastrella, Chevelle Lattimore, David Laube, Eric Lauzon, Jeanne
e, Luann Lee, Misun Lee, Dana Lee, Bryan Leigh, Justin Leighty, John Leonard, Julie LePier, Brian Less, Christopher LeTourneau, Janene Leventhal, N	Nichelle Lewis, Yan-Ping Li, Stefano Liparoto, Song Liu, Richard Lizambri, Alessandro Lobbia, Andrea Loewen-Rodriguez, Anthony Loffredo, Ulysses Logan, Kip Lowery, Kent Lowery, Katherine Loya-Dial, Jim Lunsford, William Lynch, Robert MacGillis, Lydia
- Januaria Manana Marii Mariil Mata Daniel Manaeld Jun Marinia Dan Madelo Midala Madal Adama Mankall Chuna Mankall J	Territor Marin Mart Mannale Cardin Marce Dalard Marce Cardin Marted Cardin Martine Marine Marine Martine Cardin Martine Cardin Martine Martine Cardin
a, Jusuector Magana, Mariju Magiti, Fatrick Manis, Daniet Manguti, Juan Maniquis, Kuy Mantuti, Micholas Market, Auonna Marshatt, Steven Marshatt, J	שייווויור או וווי, או א אוטנטא (בוווטר אסטון, אטוור אסטון, שווויבי אסטו, בשווויבי אסטון אטוויבי אסטון, אריוו אסטון איז איז אוטנטא איז איז איז איז איז איז איז איז איז אי
nt Meeks, Victor Meisenhelder, James Merritt, Elisabeth Mertsching, Maurice Mezzino, Robert Middien, Monica Milam, Kevin Milgrim, Cynthia Milton,	, Petey Mishlove, George Missailidis, Geralyn Mitchell, David Mitchell, Eani Mitchell, Fanzia Mohammed, Rebecca Molnar, Joseph Molon, Michael Molany, Marguerite Montgomery, Erika Mora, Anthony Morandi, Ronald Morena, Carol Morgan,
ee Morris, America Morris, Lyle Mowery, Javier Mozo Jimenez, Pratik Multani, Carlos Munera, Tracey Murphy, Lisa Musil, Deanna Myers. Havdeh Nasizad	adeh, Erik Nelson, James Neville, Roland Newman, Mai-Lan Nguyen, Mai HoaNguyen, Mich Nichdas, Wolfgang Nee, Richard Noll, Jr., Zoe Norris, Paul Norris, Alexa Newale, Mary Helena O'Beime, Loretta O'Neil, Kevin O'Beille, Scott Obershalt.
Oehler, Teresa Olejmik, Jessica Olson, Jean Olsson, Mahalia Ong, Eric Ople, Maria Ordonez, John Ortler, Douglas Osborne, Norman Padre, Tina Pagan,	, Rathleen Patter, Li-Zhen Pan, Christine Pan, Lillah Panglinan, Richard Panlan, Laurie Pape, Wendy Parker, Nuchat Pathan, Tamara Patterson, Robert Peach, Therese Persa, Lidia Perone, Daniel Perret, Heather Perrin, Dean Petree, Christine Pham, Anh-Thu
Samantha Phan, John Piebel, John Pieracci, Amy Pierce, Matthew Pino, Michelle Plageman, Robert Pollard, Chad Pollinger, Janine Pool, Richard Pott	ts, Bruce Powell, Jerrie Powell, Barbara Pyle, Luis Quintana, Darko Radovanovic, Stacey Ragan, Soheil Rahmati, Maria Ramirez, William Rastetter, Roya Ravanhahhih Pourmand, Vincent Reardon, Michell Reff, Nathan Regimbal, Michelle Reid, Yan Ren, Elliot
Tammu Raver Brice Anthony Paymen John Phader Victor Richter Antonia Die James Diles their Dies Freder Died to the Brites to the Br	Scher State
rammy keyes rrice, Antiony keynoso, John Miloues, Vickle Richter, Antonno Rico, James Riter, Staci Ritey, Larolyn Ritch, Linda Robertson, Wanda H	nommen and neuronal American Andrigate, court Koungate, and Koungate
, Sophia Royer, Debra Rozacky, Joseph Rubio, Michael Rudolf, Stephanie Rudy, Steven Ruhl, William Rushing, Alison Russell, Jason Russell, Peter Russ	sso, Thomas Ryskamp, Kouriol Safrang, Edwin Safr ar, Laura Salmeron, Susan Sanchez, Patrick Sanders, Denis Santoro, Loic Scales, Amy Scheir, Susan Schmitt, Philip Schneider, Jacqueline Schoppe, Carolynn Schoppe, Christina Schwalbe, Nary Schwalen,
chwartz, Heather Scott, Neno Segura, Arlene Sereno, Amal Shahtout, Diane Shanahan, Cynthia Sharrott, Leslie Shelly, David Shen, Michael Shen, Fel	sticity Shen, William Shectowsky, Michael Shiel',]eb. v Shook, Steven Shuey, Raymundo Sidon, Baymond Sievers, Ruben Silva, Tamara Silverstein, Bradford Simmans, Justin Sins, Adnan Siraj, Jon Smith, Sharon Smith, Peter Smith, Sandra Smith, Peter Smith, Sandra Smith, Peter Smith, Sandra Smith, Peter Smith, Sandra Smith, Peter Smith, Sandra Smith, Peter Smith, Sandra Smith, Peter Smith, Sandra Smith, Peter Smith, Sandra Smith, Peter Smith, Sandra Smith, Sandra Smith, Peter Smith, Sandra Smith, Peter Smith, Sandra Smith, Peter Smith, Sandra Smith, Peter Smith, Sandra Smith, Peter Smith, Sandra Smith, Peter Smith, Sandra Smith, Peter Smith, Sandra Smith, Peter Smith, Sandra Smith, Peter Smith, Sandra Smith, Peter Smith, Sandra Smith, Peter Smith, Sandra Smith, Sandra Smith, Peter Smith, Pete
, Filifaiesea Smolinski, Tracey Snipas, Alan Sonnenfeld, Stephen Sorenson, Heidi Spanish, Aimee Squires, Christopher Stanley, Christian Stansbury	at Stedman, Michael Stevenson, wansey Stewart, Christophe, avewart, Sophia Stewart-Torter, Stine, Beverly Stowe, Stacey Surina, Deanna Swift-Everett, Kevin Swint, Assif Taki, Mylene Talabardon, Hector Tamburini, Susan Tamraz, Sherry Tamura,
ung Tang, Lori Taylor-Mitchell, Aron Thall, Noppawan Thiemthath, Donna Thomas, Jorg Thommes, Mark Thompson, Philip Thompson, Sheri Tir 🚽 K	Kenneth Tolog, Delar Tollenton, Jessica Torres, Jaime Torrington, Mark Toltrritis, Jahn Tuley, Elleen Tupma del Upham, Leopoldo Urrutia, Jamie Utecht, Teresa Varela, Nicolas Vargas, Chester Varms, Christopher Varms, Victor Vazquez, Jr., Javier Velazquez,
ra Vickare Charan Vidal Chiday Vichmann Michael Villacerta Debra Villanyana Chiday Vitae Katia Vie William Vieth Lannia VII. Michael W	IDEC's high standards are reflected in
a vickets, silaron vical, sinney vienniann, michaet vittacorta, bebla vittanueva, sinney vicas, katte vo, mittann voti, comme vo, michaet w	the quality of its employees as well as
ley, Laurie Whitesel, Karin Whittaker, Michael Wiebe, Mark Wiggins, Robert Wiley, David Wilkinson, John Williams, James Williams, Wayne Wi 💦 , Erne	est Wingo, Donald Winterton, Amy Wise-Bacis, Christina Wong, Danny Wong, Lyle Wood, Kenneth Woolcott, Winght, Xiufeng Wu, Donald Wuchterl, Michelle Wyckoff, Karen Wylie, Sue Wylie, Deloris Wynne, Tzung HorngYang, James Yansch, Steven Young
han Yraceburn, Yufeng Zhai, Xiang Zhang, Kim Zolezzi, Karen Zoller, John Aguilar, Eric Ailor, David Ainsworth, Jeremy Aldworth, Elaine Alexa r, Ba	its products. As affirmed in IDEC's saha Alkanwery, Katherine Allen, Kohert Allen, Carmen Altaminano, Anthony Alvarez, David Aman, Jerry / 2rg. Patrick Ancmon, Darrell Anderson, James Anderson, Marissa Andrade, Mary Andreata, Rhonda Angele, Maria Angeles, Martin Antony, Marissa
	corporate values, the actions of these
ta, Erwin Armas, Kim Armstrong, Maria Arroyo-Asbagh, Melissa Arterburn, Karen Atkinson, Michael Bacica, Matthew Bacis, Michelle Bailey, Ti: Bair	ind, Ben Bakarnik, Thyliis Balan, Mark Balahnin, Edgar Ballesteros, Edward Ballesteros, Lionel Barbora, D e Barge, Richard Barnett, Donna Barnett, Sandra Barton, Thomas Basinski, Walter Bateman, Bruce Batson, Mark Baum, Matthew Beaulieu, Laurie individuals and of the company as a
Behler, Julia Benedetti, Rita Bergers, Lisa Berquist, Wolfgang Berthold, Christina Bevilacqua, Carolin Bevis, Kathleen Bigelow-I 🛛 Jck, A	
	whole are reated in truct honecty
1/2 Z - Tax Description Time Denvise David Deced Amende Deckhauser Takin Description Care Denver Shourd Duckl. Cod Buller (whole are rooted in trust, honesty, Chiefe are rooted in trust, honesty,
, Ina Brenneise, Tina Brewer, David Broad, Amanda Brokhausen, Tobin Brosnahan, Sara Brown, Steven Burka, Carl Bullen, Carl	Christopher Burman, Laura Burness, James Burnham, Brenda Burtnett, Rudolph Bustamante, Barton Butler, Douglas 👘 👘 🛛
, Ina Brenneise, Tina Brewer, David Broad, Amanda Brokhausen, Tobin Brosnahan, Sara Brown, Steven Burks, J., Gari Bullen, C., Cari Bullen, C., Karlson, Samuel Carribucci, Matthew Carpenter, Scott Carrier, Bavid Carrillo, Cathleen Carter, Susan Cassidy, Thomas Cavare. August	Christopher Burnan, Laura Burness, James Burnham, Brenda Burnett, Budolph Bustamante, Barton Butter, Dougles 2:bba, Yolanda Cabardoc, Susan Cartelli, Bryant Cameron, John Campbell, Carol Candiano, Jeffrey Cannon, X* integrinty and a committeement to team- the Carue, Baddya Chusin, Earch Chumanne, Yu-Hsiang Chang, Shahaz Chaudhary, H., y Che, Yeau Chen, Nicole Chieffo, Leuda Ching, Paul Ching, Charmie Chingwin, Yangion Cho, Dougles, Christian, Peter Chu, N., 99
The Brewer, David Broad, Amanda Brokhausen, Tobin Brosnahan, Sara Brown, Steven Burks, J., Carl Bullen, O., Carl Bullen, J., Carlson, Samuel Carnibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Cathleen Carter, Susan Cassidy, Thomas Cavare. August Flark Jourg Cleary. Thomas Clough, Greenou fola Erancisco Colon, Barbara Compasu, June Conley, Brian Conport, Banais Conport, Banais Conport, Matthew	Christopher Burnan, Laur Burnes, James Burnham, Bende Burther, Indolph Bustamarke, Barton Butter, Dougles 2::bba, Yolanda Cabadoc, Suran Carrelli, Byant Cameron, John Campbell, Carol Candiano, Jeffrey Cannon, X* integrity and a committee to the committee to the committee to the committee to the committee of th
, In a Brenneise, Tina Brever, Bavid Broad, Amanda Brokhausen, Tobin Brosnahan, Sara Brown, Steven Bur ^{+,+} , Carl Bullen, O. A Carlson, Samuel Carribucci, Matthew Carpenter, Scott Carrier, David Carrillo, Cathleen Carter, Susan Cassidy, Thomas Cavare. Augu Janet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, M. Artistica Compeau, Lynn Conley, Brian Connors, Dennis Cooney, M.	Christopher Burnan, Laur Burnes, James Burnham, Bende Burther, Indolph Bustamarke, Barton Butter, Dougles 2::bba, Yolanda Cabadoc, Suran Carrelli, Byant Cameron, John Campbell, Carol Candiano, Jeffrey Cannon, X* integrity and a committee to the committee to the committee to the committee to the committee of th
J. In a Brenneise, Tina Brever, David Broad, Amanda Brokhausen, Tobin Brosnahan, Sara Brown, Steven Bur ^{+, ,} , Carl Bullen, I A Carlson, Samuel Carribucci, Matthew Carpenter, Scott Carrier, David Carrillo, Cathleen Carter, Susan Cassidy, Thomas Cavare. Augu Janet Clark, Joyce Cleany, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, M. 2015 De Weerd, Katherine Deane-Bousum, Jami DeBrango-Palumbo, Kathleen DeKsker, Allan Delacruz, Hugo Delgadillo, Charles Demeree, Freder Jenn	Christopher Burnan, Laur Burnes, Janes Burne
Tod Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elhayat, Cynthia Elington, Roselle Ellion, Nikel Edwards, Emelyn Eldredge, Amr Elhayat, Cynthia Elington, Roselle Ellion, Nikel Edwards, Emelyn Eldredge, Amr Elhayat, Cynthia Elington, Roselle Ellion, Nikel Edwards, Emelyn Eldredge, Amr Elhayat, Cynthia Elington, Roselle Ellion, Nikel Edwards, Emelyn Eldredge, Amr Elhayat, Cynthia Elington, Roselle Ellion, Roselle Ellion, Mark Ellion, Paul Elpers, roo Englington, Mikel Edwards, Emelyn Eldredge, Amr Elhayat, Cynthia Elington, Roselle Ellion, Dirk Ellion, Mark Ellion, Paul Elpers, roo Englington, Mikel Edwards, Emelyn Eldredge, Amr Elhayat, Cynthia Elington, Roselle Ellion, Dirk Ellion, Mark Ellion, Paul Elpers, roo Englington, Mikel Edwards, Emelyn Eldredge, Amr Elhayat, Cynthia Elington, Roselle Ellion, Dirk Ellion, Mark Ellion, Paul Elpers, roo Englington, Mikel Edwards, Emelyn Eldredge, Amr Elhayat, Cynthia Elington, Roselle Ellion, Dirk Ellion, Mark Ellion, Paul Elpers, roo Englington, Mikel Edwards, Emelyn Eldredge, Amr Elhayat, Cynthia Elington, Roselle Ellion, Dirk Ellion, Mark Ellion, Paul Elpers, roo Englington, Mikel Edwards, Emelyn Eldredge, Amr Elhayat, Cynthia Elington, Roselle Ellion, Dirk Ellion, Paul Elpers, roo Englington, Mikel Edwards, Emelyn Eldredge, Amr Elhayat, Cynthia Elington, Roselle Ellion, Dirk Ellion, Paul Elpers, roo Englington, Mikel Edwards, Emelyn Eldredge, Amr Elhayat, Cynthia Elington, Roselle Ellion, Dirk Ellion, Paul Elpers, roo Englington, Mikel Edwards, Emelyn Eldredge, Amr Elhayat, Cynthia Elington, Roselle Ellion, Edwards, Emelyn Eldredge, Ellion Ellion, Edwards, Ellion Ellion, Ellion, Paul Elpers, roo Englington, Mikel Edwards, Emelyn Eldredge, Amr Ellion E	Christopher Burnan, Laun Burnes, Janes Burnes, Burnes, Janes Burnes, Janes Burnes, Janes Burnes, Janes Burnes, Jan
7. Ina Brenneise, Tina Brever, David Broad, Amanda Brokhausen, Tobin Brosnahan, Sara Brown, Steven Bur ^{1,1} , Garl Bullen, O A Carison, Samuel Carribucci, Matthew Carpenter, Scott Carrier, David Carrillo, Cathleen Carter, Susan Cassidy, Thomas Cavare. Augu Janet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, M. 1995 De Weerd, Katherine Deane-Bousum, Jami DeBrango-Palumbo, Kathleen Dekoker, Allan Delacruz, Hugo Delgadillo, Charles Demeree, Freder Jenn Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, (a Englistic Marker, Cart	Christopher Burnan, Laur Burnes, Janes Burne
7. Ina Brenneise, Tina Brewer, David Broad, Amanda Brokhausen, Tobin Brosnahan, Sara Brown, Steven Burk, and Carl Bullen, C. Carl Bullen, C. Carloson, Samuel Carribucci, Matthew Carpenter, Scott Carrier, David Carrillo, Cathleen Carter, Susan Cassidy, Thomas Cavare. Augut, Janet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, M. iritit De Weerd, Katherine Deane-Bousum, Jami DeBrango-Palumbo, Kathleen DeKoker, Allan Delacruz, Hugo Delgadillo, Charles Demree, Freder Jenn Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, in a Engi riy Fields. Susette Fino, Jonathan Fitchett, Kenneth Fite, Edith Fite, Joyce Fleming, Geraldine Fontblas, Sharlene Forbes, Helen Forrester, Li ov. Ch.	Christopher Burnan, Lans Burnes, Lines Burnes, Marke Burnes, Marke Burnes, Marke Burnes, Marke Burnes, Marke Burnes, Kante Burnes, Marke Burnes, Kante Burnes, Marke Burnes, Kante Burnes, Marke Burnes, Kante Burnes, Marke Burnes, Kante Burnes, Marke Burnes, Kante Burnes, Bur
The Brenneise, Tina Brever, David Broad, Amanda Brokhausen, Tobin Brosnahan, Sara Brown, Steven Bur ^{+,+} , Carl Bullen, C. A Carlson, Samuel Camibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Cathleen Carter, Susan Cassidy, Thomas Cauge, A Carlson, Samuel Carriton, Jani DeBrango-Palumbo, Kathleen Dekker, Allan Delacruz, Hugo Delgadillo, Charles Demerce, Freder Jenn Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, (a Eng rly Fields, Susette Fino, Jonathan Fitchett, Kenneth Fite, Edith Fite, Joyce Fleming, Geraldine Fontillas, Sharlene Forbes, Helen Forrester, Li ox, Ch ch, Akaterini Gekas, Lary George, Anthony Gerran, Swarnalata Chanta, Brian Giambrone, Jack Glese, Catherine Gilbody, Judth Giri, Leonar	Christopher Burnan, Laun Burnes, Janes Burnes, Burnes, Janes Burnes, Burnes, Janes Burnes, Janes Burnes, Janes Bur
The answerie of the second secon	Christopher Burnan, Lans Burnes, Lines Burnes, Marke Burnes, Marke Burnes, Marke Burnes, Marke Burnes, Marke Burnes, Kante Burnes, Marke Burnes, Kante Burnes, Marke Burnes, Kante Burnes, Marke Burnes, Kante Burnes, Marke Burnes, Kante Burnes, Marke Burnes, Kante Burnes, Bur
Toda Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elihayat, Cymthia Elington, Roselle Elitson, Dirk Elison, Nark Elison, Paul Elpers, L an Enginton, Sansette Fino, Jonathan Fitchett, Kenneth Fite, Edith Fite, Joyce Fleming, Geraldine Fontbilas, Sharlene Forber, Helen Forrester, L oc. Ch ch, Alkaterini Gekas, Larry George, Aenthony Gerran, Swarnalata Ghanta, Brian Giambrone, Jack Giese, Catherine Gilbody, Judith Giri, Leonare, dan decer, Dennis Hallissey, Leslie Halsey, Kenneth Hamilton, Nabil Hanna, John Hanson, Kandasamy Hartharan, Steven Harries, Jonathan Hartley, .	Christopher Burnan, Lans Burnes, Lines Burnes, Marke Burnes, Marke Burnes, Marke Burnes, Marke Burnes, Marke Burnes, Kante Burnes, Marke Burnes, Kante Burnes, Marke Burnes, Kante Burnes, Marke Burnes, Kante Burnes, Marke Burnes, Kante Burnes, Marke Burnes, Kante Burnes, Bur
A Carlson, Samuel Carnibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Cathleen Carter, Susan Cassidy, Thomas Cavare. Augu Janet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, M: Jie Weerd, Katherine Deane-Bousum, Jami DeBrango-Palumbo, Kathleen DeKoker, Allan Delacruz, Hugo Delgadillo, Charles Demeree, Freder Jenn Todd Edgington, Mikel Edwards, Enelyn Eldredge, Amr Elikhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, / a Eng rly Fields, Susette Fino, Jonathan Fitchett, Kenneth Fite, Edith Fite, Joyce Fleming, Geraldine Fontillas, Sharlene Forbes, Helen Forrester, Li ch, Aikaterini Gekas, Larry George, Anthony Gerran, Swarnalata Ghanta, Brian Giambrone, Jack Giese, Catherine Gilbody, Judith Giri, Leonarc dian acker, Dennis Hallissey, Leslie Halsey, Kenneth Hamilton, Nabil Hanna, John Hanson, Kandasamy Hariharan, Steven Harries, Jonathan Hartley, .	Christopher Burnan, Lans Burnes, Lines Burnes, Marke Burnes, Marke Burnes, Marke Burnes, Marke Burnes, Marke Burnes, Kante Burnes, Marke Burnes, Kante Burnes, Marke Burnes, Kante Burnes, Marke Burnes, Kante Burnes, Marke Burnes, Kante Burnes, Marke Burnes, Kante Burnes, Bur
¹ A Carloon, Samuel Carnibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Cathleen Carter, Susan Cassidy, Thomas Cavare. Augu Janet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, Mi Trist De Weerd, Katherine Deane-Bousum, Jami DeBrango-Palumbo, Kathleen DeKoker, Allan Delacruz, Hugo Delgadillo, Charles Demeree, Freder Jenn Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, (a Engl rly Fields, Susette Fino, Jonathan Fitchett, Kenneth Fite, Edith Fite, Joyce Fleming, Geraldine Fontillas, Sharlene Forbes, Helen Forrester, Li ch, Aikaterini Gekas, Larry George, Anthony Gerran, Swarnalata Ghanta, Brian Giambrone, Jack Giese, Catherine Gilbody, Judith Giri, Leonare deker, Dennis Hallissey, Leslie Halsey, Kenneth Hamilton, Nabil Hanna, John Harson, Kandasamy Hariharan, Steven Harries, Jonathan Hartley, . h ense, Eric Hicks, Basim Hial, Serena Hill, Junius Hill, Timothy Hill, Ashlee Hill, Bryan Hirschon, Carl Hixon, Hanh ThiHoang, Michael Hoar, Elaine	Christopher Barnan, Laun Barnes, Janes Bonnes, Bonnes, B
¹ A Carloon, Samuel Carnibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Gathleen Carter, Susan Cassidy, Thomas Cavare. Agu 2 Janet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, M. ¹ rist 2 De Weerd, Katherine Deane-Bousum, Jami DeBrango-Palumbo, Kathleen DeKoker, Allan Delacruz, Hugo Delgadillo, Charles Demeree, Freder Jenn Todd Edgington, Mikel Edwards, Emelyn Eldradge, Amr Elkhayat, Cynthia Eilington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, (a Eng 1 rly Fields, Susette Fino, Jonathan Fitchett, Kenneth Fite, Edith Fite, Joyce Fleming, Geraldine Fontbilas, Sharlene Forbes, Helen Forrester, Li ox, Ch ch, Alkaterini Gekas, Larry George, Anthony Gerran, Swarnalata Ghanta, Brian Giambrone, Jack Giese, Catherine Gilbody, Judith Giri, Leonarc Acker, Dennis Hallissey, Leslie Halsey, Kenneth Hamilton, Nabil Hanna, John Hanson, Kandasamy Hariharan, Steven Harrics, Jonathan Hartley, . h Hess, Eric Hicks, Basim Hilal, Serena Hill, Junius Hill, Timothy Hill, Ashlee Hill, Bryan Hirschon, Cart Hixon, Hanh ThiHoang, Michael Hoar, Elaine is, Shino Inouye, Jesse Ivers, III, John Jacamin, Peter James, Douglas Jankowski, Kurt Janson, Kristine Jaramillo, Greer Jattan, Amba Jember, Liyin	Christiane Burnham, Bannes Jaame Burnham, Bannes Jaame Burnham, Bannes Jahmes Mather, Bande Burnham, Bannes Jahmes Marker, Bande Burnham, Bannes Marker, Bander Burnham, Bannes Marker, Bander Burnham, Bannes Marker, Bander Burnham, Bannes Marker, Bander Burnham, Bannes Marker,
¹ A Carloon, Samuel Carnibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Gathleen Carter, Susan Cassidy, Thomas Cavare. Agu 2 Janet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, M. ¹ rist 2 De Weerd, Katherine Deane-Bousum, Jami DeBrango-Palumbo, Kathleen DeKoker, Allan Delacruz, Hugo Delgadillo, Charles Demeree, Freder Jenn Todd Edgington, Mikel Edwards, Emelyn Eldradge, Amr Elkhayat, Cynthia Eilington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, (a Eng 1 rly Fields, Susette Fino, Jonathan Fitchett, Kenneth Fite, Edith Fite, Joyce Fleming, Geraldine Fontbilas, Sharlene Forbes, Helen Forrester, Li ox, Ch ch, Alkaterini Gekas, Larry George, Anthony Gerran, Swarnalata Ghanta, Brian Giambrone, Jack Giese, Catherine Gilbody, Judith Giri, Leonarc Acker, Dennis Hallissey, Leslie Halsey, Kenneth Hamilton, Nabil Hanna, John Hanson, Kandasamy Hariharan, Steven Harrics, Jonathan Hartley, . h Hess, Eric Hicks, Basim Hilal, Serena Hill, Junius Hill, Timothy Hill, Ashlee Hill, Bryan Hirschon, Cart Hixon, Hanh ThiHoang, Michael Hoar, Elaine is, Shino Inouye, Jesse Ivers, III, John Jacamin, Peter James, Douglas Jankowski, Kurt Janson, Kristine Jaramillo, Greer Jattan, Amba Jember, Liyin	Christopher Burnan, Laur Burnes, Janes Burne
¹ A Carlson, Samuel Carnibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Gathleen Carter, Susan Cassidy, Thomas Cavare. Aggu 3 anet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, M. ¹ irist De Weerd, Katherine Deane-Bousum, Jami DeBrango-Palumbo, Kathleen DeKoker, Allan Delacruz, Hugo Delgadillo, Charles Demeree, Freder Jenn Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, (a Eng rdy Fields, Susette Fino, Jonathan Fitzhett, Kenneth Fitz, Edith Fitz, Joyce Fleming, Geraldine Fontillas, Sharlene Forbes, Helen Forrester, Li ox, Ch ch, Aikaterini Gekas, Larry George, Anthony Gerran, Swarnalata Ghanta, Brian Giambrone, Jack Glese, Catherine Gilbody, Judith Giri, Leonarc dara, Dennis Hallissey, Leslie Halsey, Kenneth Hamitton, Nabil Hanna, John Hanson, Kandasamy Hariharan, Steven Harries, Jonathan Hartley, - h Hess, Eric Hicks, Basim Hilal, Serena Hill, Junius Hill, Timothy Hill, Ashlee Hill, Byan Hirschon, Carl Hixon, Hanh ThiHoang, Michael Hoar, Elaine io, Shino Inouye, Jesse Ivers, III, John Jacanin, Peter James, Douglas Jankowski, Kurt Janson, Kristine Jaramillo, Greer Jatan, Amha Jember, Liyin n ehery, Steven Kelly, Steven Kendall, Kristine Kepler, Janice Kern, Daniel Kim, Yune Kim, Martin King, Timothy Kincher, Terry Klinker, William Ko	Christiane Burnham, Bannes Jaame Burnham, Bannes Jaame Burnham, Bannes Jahmes Mather, Bande Burnham, Bannes Jahmes Marker, Bande Burnham, Bannes Marker, Bander Burnham, Bannes Marker, Bander Burnham, Bannes Marker, Bander Burnham, Bannes Marker, Bander Burnham, Bannes Marker,
¹ A Carloon, Samuel Carnibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Gathleen Carter, Susan Cassidy, Thomas Cavare. Aggu Janet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, Ma Trist De Weerd, Katherine Deane-Bousum, Jami DeBrango-Palumbo, Kathleen Dekoker, Allan Delacruz, Hugo Delgadillo, Charles Demeree, Freder Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Carlor Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Carlor ty Fields, Susette Fino, Jonathan Fitchett, Kenneth Fite, Edith Fite, Joyce Fleming, Geraldine Fontillas, Sharlene Forbes, Helen Forrester, Li ch, Akaterini Gekas, Larry George, Anthony Gerran, Swarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Gilbody, Judith Giri, Leonart Marker, Dennis Hallissey, Leslie Haleey, Kenneth Hamilton, Nabil Hanna, John Hanson, Kandasamy Hartharan, Steven Harries, Jonathan Hartley, . h Hess, Eric Hicks, Basim Hilal, Serena Hill, Junius Hill, Timothy Hill, Ashlee Hill, Bryan Hirschon, Carl Hixon, Hant ThiHoang, Michael Hoar, Elaine ko, Shino Inouye, Jasse Ivers, III, John Jacanin, Peter Jamee, Douglas Jankowski, Kurt Janson, Kristine Jaramillo, Greer Jattan, Amha Jember, Liyin n Kehry, Steven Kelly, Steven Kendall, Kristine Kepler, Janice Kern, Daniel Kim, Yune Kim, Martin King, Timothy Kirchner, Terry Klinker, William Klo x, Jeliani Larson, Cleofe Lastrella, Chevelle Lattimore, David Laube, Eric Lauzon, Jeanne LeVoie, Luann Lee, Misun Lee, Bryan Leigh, Justi	Christopher Barnan, Laun Banness, Jannes Banness, Jannes Barne
¹ A Carloon, Samuel Carnibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Cathleen Carter, Susan Cassidy, Thomas Cavare. Augu Janet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, Ma Tode Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, Ma Tode Edgington, Mikel Edwards, Emelyn Eldredge, Amr Eikhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Case Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Eikhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Case Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Eikhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Case Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Eikhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Case Ch, Alkaterini Gekas, Larry George, Anthony Gerran, Svarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Cillbody, Judith Giri, Leonare Ch, Alkaterini Gekas, Larry George, Anthony Gerran, Svarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Cillbody, Judith Giri, Leonare Ch, Aikaterini Gekas, Larry George, Anthony Gerran, Svarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Cillbody, Judith Giri, Leonare Ch, Basim Hial, Serena Hill, Junius Hill, Timothy Hill, Ashlee Hill, Bryan Hirschon, Carl Hixon, Hant ThiHoang, Michael Hoar, Elaine is, Shino Inouge, Jesse Ivers, III, John Jacanin, Peter James, Douglas Jankowski, Kurt Janson, Kristine Jaramillo, Greer Jattan, Amha Jember, Llym n Kehry, Steven Kelly, Steven Kendall, Kristine Kepler, Janice Kern, Daniel Kim, Yune Kim, Martin King, Timothy Kirchner, Terry Kinker, William Klo x, Lellani Larson, Cleofe Lastrella, Chevelle Lattimore, David Laube, Fric Lauzen, Jeanne LaVoie, Luann Lee, Misun Lee, Dana Lee, Bryan Leigh, Justi y, Kent Lowey, Katherine Loya-Dial, Jin Lunsford,	Christone Burnham, Burne Burnham, Bunes Burnes, Burnes, Burnes Burnes, Rumes Bu
¹ A Carloon, Samuel Carnibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Cathleen Carter, Susan Cassidy, Thomas Cavare. Augu Janet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, Ma Tode Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, Ma Tode Edgington, Mikel Edwards, Emelyn Eldredge, Amr Eikhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Case Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Eikhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Case Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Eikhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Case Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Eikhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Case Ch, Alkaterini Gekas, Larry George, Anthony Gerran, Svarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Cillbody, Judith Giri, Leonare Ch, Alkaterini Gekas, Larry George, Anthony Gerran, Svarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Cillbody, Judith Giri, Leonare Ch, Aikaterini Gekas, Larry George, Anthony Gerran, Svarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Cillbody, Judith Giri, Leonare Ch, Basim Hial, Serena Hill, Junius Hill, Timothy Hill, Ashlee Hill, Bryan Hirschon, Carl Hixon, Hant ThiHoang, Michael Hoar, Elaine is, Shino Inouge, Jesse Ivers, III, John Jacanin, Peter James, Douglas Jankowski, Kurt Janson, Kristine Jaramillo, Greer Jattan, Amha Jember, Llym n Kehry, Steven Kelly, Steven Kendall, Kristine Kepler, Janice Kern, Daniel Kim, Yune Kim, Martin King, Timothy Kirchner, Terry Kinker, William Klo x, Lellani Larson, Cleofe Lastrella, Chevelle Lattimore, David Laube, Fric Lauzen, Jeanne LaVoie, Luann Lee, Misun Lee, Dana Lee, Bryan Leigh, Justi y, Kent Lowey, Katherine Loya-Dial, Jin Lunsford,	Christone Burnham, Same Burnham, Banke Burnham, Ban
A Cardoon, Samuel Carnibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Cathleen Carter, Susan Cassidy, Thomas Cavare. Ageu J anet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, M. Siti De Weerd, Katherine Deane-Bousum, Jami DeBrango-Palumbo, Kathleen DeKoker, Allan Delacruz, Hugo Delgadillo, Charles Demeree, Freder Jann Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Ekhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, I a Ingi rly Fields, Susatte Fino, Jonatham Fitchett, Kenneth Fite, Edith Fite, Joyce Reming, Geraldine Fontilas, Sharlene Forbes, Helen Forrester, L ov, Ch ch, Aikaterini Gekas, Larry George, Anthony Gerran, Swarnalata Ghanta, Brian Giambrone, Jack Giese, Catherine Gilbody, Judith Giri, Leonart dana cker, Dennis Hallissey, Leslie Halsey, Kenneth Hamilton, Nabil Hanna, John Hanson, Kandasamy Hariharan, Steven Harries, Jonathan Hartley, - h Hess, Eric Hicks, Basim Hial, Serena Hill, Junius Hill, Timothy Hill, Ashlee Hill, Bryan Hirschon, Cart Hixon, Hanh ThiHoang, Michael Hoar, Elaine is, Shino Inouye, Jasse Ivers, III, John Jacanin, Peter James, Douglas Jankowski, Kurt Janson, Kristine Jaramillo, Greer Jattan, Amha Jember, Liyin n Kehry, Steven Keily, Steven Kendall, Kristine Kepler, Janice Kern, Daniel Kim, Yune Kim, Martin King, Timothy Kirchner, Terry Klinker, William Klo x, Leilani Larson, Cleofe Lastrella, Chevelle Lattimore, David Laube, Fric Lauzon, Jeanen LaVoie, Laann Lee, Misun Lee, Brana Leigh, Jactt y, Kent Lowery, Katherine Loya-Dial, Jin Lunsford, William Lynch, Robert MacGillis, Lydia Madura, Josuector Magana, Marijo Magill, Patrick Mains, Da McCuzkey, Kely Connell, David McKinley, Karen McLachlan, Lisa McLain, Soria Medder, Lamont Meeles, Victor Meisenhelder, James Merritt, Elia	Christone Burnham, Burne Burnham, Bunes Burnes, Burnes, Burnes Burnes, Rumes Bu
A Cardoon, Samuel Carnibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Gathleen Carter, Susan Cassidy, Thomas Cavare. Agu J anet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, M. Jrist De Weerd, Katherine Deane-Bousum, Jami DeBrango-Palumbo, Kathleen DeKoker, Allan Delacruz, Hugo Delgadillo, Charles Demeree, Freder Jann Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, (a Eng try Fields, Susette Fino, Jonathan Fitchett, Kenneth Fite, Edith Fite, Joyce Fleming, Geraldine Fontillas, Sharlene Forbes, Helen Forrester, Li ox, Ch ch, Alkaterini Gekas, Larry George, Anthony Gerran, Swarnalata Ghanta, Brian Giambrone, Jack Glese, Catherine Gilbody, Judith Giri, Leonarc Akkaterini Gekas, Larry George, Anthony Gerran, Swarnalata Ghanta, Brian Giambrone, Jack Glese, Catherine Gilbody, Judith Giri, Leonarc Akkaterini Gekas, Larry George, Anthony Gerran, Swarnalata Ghanta, Brian Giambrone, Jack Glese, Catherine Gilbody, Judith Giri, Leonarc Akkaterini Gekas, Larry George, Anthony Gerran, Swarnalata Ghanta, Brian Giambrone, Jack Glese, Catherine Gilbody, Judith Giri, Leonarc Acker, Dennis Hallissey, Leslie Halsey, Kenneth Hamilton, Nabil Hanna, John Hanson, Kandasamy Hariharan, Steven Harrics, Jonathan Hartley, . h Hess, Eric Hicks, Basim Hilal, Serena Hill, Junius Hill, Timothy Hill, Ashlee Hill, Bryan Hirschon, Cart Hixon, Hanh ThiHoang, Michael Hoar, Elaine is, Shino Inouye, Jesse Ivers, III, John Jacanin, Peter James, Douglas Jankowski, Kurt Janson, Kristine Jaramillo, Greer Jattan, Amha Jember, Liyin n Kehy, Steven Kenly, Steven Kendall, Kristine Kepler, Janice Kern, Daniel Kim, Yune Kim, Martin King, Timothy Kirchner, Terry Klinker, William Klo x, Leilani Larson, Cleofe Lastrella, Chevelle Lattimore, David Laube, Fric Lauzon, Jeanne LaVoie, Luann Lee, Misun Lee, Dana Lee, Bryan Leigh, Justi y, Kert Lowey, Katherine Loya-Dial, Jin	Christian Burnan, Jaam Burnes, Janes Burnes,
A Cardoon, Samuel Carnibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Gathleen Carter, Susan Cassidy, Thomas Cavare. Agus J anet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, Mr Site Weerd, Katherine Deane-Bousum, Jami DeBrango-Palumbo, Kathleen DeKoker, Allan Delacruz, Hugo Delgadillo, Charles Demeree, Freder Jenn Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, (a Engi Try Fields, Susette Fino, Jonathan Fitchett, Kenneth Fite, Edith Fite, Joyce Fleming, Geraldine Fontillas, Sharlene Forbes, Helen Forrester, Li co, Ch ch, Alkaterini Gekas, Larry George, Anthony Geran, Swarnalata Ghanta, Brian Giambrone, Jack Glese, Catherine Gilbody, Judith Giri, Leonar ch, Aikaterini Gekas, Larry George, Anthony Geran, Swarnalata Ghanta, Brian Giambrone, Jack Glese, Catherine Gilbody, Judith Giri, Leonar ch, Aikaterini Gekas, Larry George, Anthony Geran, Swarnalata Ghanta, Brian Giambrone, Jack Glese, Catherine Gilbody, Judith Giri, Leonar ch, Aikaterini Gekas, Larry George, Anthony Geran, Swarnalata Ghanta, Brian Giambrone, Jack Glese, Catherine Gilbody, Judith Giri, Leonar ch, Aikaterini Gekas, Larry George, Anthony Geran, Swarnalata Ghanta, John Hanson, Kandasamy Hariharan, Steven Harries, Jonathan Hartley, . h Hess, Eric Hicks, Basim Hilal, Serena Hill, Junius Hill, Timothy Hill, Ashlee Hill, Byan Hirschon, Carl Hixon, Hanh ThiHoang, Michael Hoar, Elaine io, Shino Inouye, Jesse Ivers, III, John Jacanin, Peter James, Douglas Jankowski, Kurt Janson, Kristine Janamillo, Greer Jatan, Amha Jember, Liyin n Kehry, Steven Kelly, Steven Kendall, Kristine Kepler, Jamice Kern, Daniel Kim, Yune Kim, Martin King, Timothy Kirchner, Terry Klinker, William Kio s, Leilani Larson, Gleofe Lastrella, Chevelle Lattimore, David Laube, Fric Lauzon, Jeanne LaVoie, Luann Lee, Misun Lee, Dana Lee, Bryan Leigh, Jacti y, Kent Lewery, Katherine Loya-Dial,	Cirk under darages darabase, bande darabase, bande batter, badeh battarabe, batter batter, batte
A Cardoon, Samuel Carnibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Gathleen Carter, Susan Cassidy, Thomas Cavare. Agus J anet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, Mr Site Weerd, Katherine Deane-Bousum, Jami DeBrango-Palumbo, Kathleen DeKoker, Allan Delacruz, Hugo Delgadillo, Charles Demeree, Freder Jenn Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, (a Engi Try Fields, Susette Fino, Jonathan Fitchett, Kenneth Fite, Edith Fite, Joyce Fleming, Geraldine Fontillas, Sharlene Forbes, Helen Forrester, Li co, Ch ch, Alkaterini Gekas, Larry George, Anthony Geran, Swarnalata Ghanta, Brian Giambrone, Jack Glese, Catherine Gilbody, Judith Giri, Leonar ch, Aikaterini Gekas, Larry George, Anthony Geran, Swarnalata Ghanta, Brian Giambrone, Jack Glese, Catherine Gilbody, Judith Giri, Leonar ch, Aikaterini Gekas, Larry George, Anthony Geran, Swarnalata Ghanta, Brian Giambrone, Jack Glese, Catherine Gilbody, Judith Giri, Leonar ch, Aikaterini Gekas, Larry George, Anthony Geran, Swarnalata Ghanta, Brian Giambrone, Jack Glese, Catherine Gilbody, Judith Giri, Leonar ch, Aikaterini Gekas, Larry George, Anthony Geran, Swarnalata Ghanta, John Hanson, Kandasamy Hariharan, Steven Harries, Jonathan Hartley, . h Hess, Eric Hicks, Basim Hilal, Serena Hill, Junius Hill, Timothy Hill, Ashlee Hill, Byan Hirschon, Carl Hixon, Hanh ThiHoang, Michael Hoar, Elaine io, Shino Inouye, Jesse Ivers, III, John Jacanin, Peter James, Douglas Jankowski, Kurt Janson, Kristine Janamillo, Greer Jatan, Amha Jember, Liyin n Kehry, Steven Kelly, Steven Kendall, Kristine Kepler, Jamice Kern, Daniel Kim, Yune Kim, Martin King, Timothy Kirchner, Terry Klinker, William Kio s, Leilani Larson, Gleofe Lastrella, Chevelle Lattimore, David Laube, Fric Lauzon, Jeanne LaVoie, Luann Lee, Misun Lee, Dana Lee, Bryan Leigh, Jacti y, Kent Lewery, Katherine Loya-Dial,	Christian Burnan, Jaam Burnes, Janes Burnes,
A Cardoon, Samuel Carnibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Gathleen Carter, Susan Cassidy, Thomas Cavare. Ageu J anet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, Ma De Weerd, Katherine Deane-Bousum, Jami DeBrango-Palumbo, Kathleen DeKoker, Allan Delacruz, Hugo Delgadillo, Charles Demeree, Freder Jenn Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Eikhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, L. a Eng rhy Fields, Susette Fino, Jonathan Fitchett, Kenneth Fite, Edith Fite, Joyce Fleming, Geraldine Fontillas, Sharlene Forbes, Helen Forrester, Li ox, Ch ch, Aikaterini Gekas, Larry George, Anthony Gerran, Swarnalata Ghanta, Brian Giambrone, Jack Glese, Catherine Gilbody, Judith Giri, Leonare teker, Dennis Hallissey, Leslie Halsey, Kenneth Hamilton, Nabil Hanna, John Hanson, Kandasamy Hariharan, Steven Harries, Jonathan Hartley, . h Hess, Eric Hicks, Basim Hilal, Serena Hill, Junius Hill, Timothy Hill, Ashlee Hill, Bryan Hirschon, Carl Hixon, Hanh ThiHoang, Michael Hoar, Elaine to, Shino Inouye, Jesse Ivers, III, John Jacanin, Peter James, Douglas Jankowski, Kurt Janson, Kristine Jaramillo, Greer Jattan, Amha Jember, Liyin n Kehry, Steven Kelly, Steven Kendall, Kristine Kepler, Janice Kern, Daniel Kim, Yune Kim, Martin King, Timothy Kirchner, Terry Klinker, William Klo x, Lelani Larson, Geofe Lastrella, Chevelle Lattimore, David Laube, Eric Lauzon, Jeanne LaVoie, Luann Lee, Misun Lee, Dana Lee, Bran Leigh, Jasti WK Lowery, Katherine Loya-Dial, Jim Luncford, William Lynch, Robert MacGillis, Lydia Madura, Josuector Magana, Marijo Magill, Patrick Mains, Da McCluskey, Kelly McConnell, David McKinley, Karen McLachlan, Lisa McLain, Soria Medder, Lumont Meeks, Victor Meisenhelder, James Merritt, Elisal koris, Alyssa Norge, Ray Helena O'Beime, Loretta O'Neil, Kevin O'Reilly, Scott Obenshain, Brian Oehier, Teresa Olejnik, Jessica Oloon, Jaan Olson, L erena, Lidia P	Cirk under darages darabase, bande darabase, bande batter, badeh battarabe, batter batter, batte
A Carloon, Samuel Carnibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Gathleen Carter, Susan Cassidy, Thomas Cavare. Aggu Janet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, Ma Tode Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, Ma Tode Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Caster Tode Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Caster Tode Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Caster the, Akaterini Gekas, Larry George, Anthony Gerran, Swarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Gilbody, Judith Giri, Leonare che, Akaterini Gekas, Larry George, Anthony Gerran, Swarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Cilbody, Judith Giri, Leonare these, Eric Hicks, Basim Hilal, Serena Hill, Junius Hill, Timothy Hill, Ashlee Hill, Bryan Hirschon, Carl Hixon, Hant ThiHoang, Michael Hoar, Elaine ko, Shino Inouye, Jesse Ivers, ITI, John Jacanin, Peter James, Douglas Jankowski, Kurt Janson, Kristine Jaramillo, Greer Jattan, Amha Jember, Liyin n Kehry, Steven Kelly, Steven Kendall, Kristine Kepler, Janice Kern, Daniel Kim, Yune Kim, Martin King, Timothy Kirchner, Terry Klinker, William Klo x, Leilani Larson, Cleofe Lastrella, Chevelle Lattimore, David Laube, Eric Lauzon, Jeanne Levie, Luann Lee, Misun Lee, Brana Lee, Bryan Leigh, Justi y, Kert Lowery, Katherine Loya-Dial, Jim Lunsford, William Lynch, Robert MacGillis, Lydia Madura, Jossector Magana, Marijo Magill, Patrick Mains, Da McCluskey, Kelly McConnell, David McKinley, Karen McLachlan, Lisa McLain, Sonia Medder, Launn Lee, Mornic, Merie, Merrit, Lisal toris, Ayasa Noerga, Nary Helena O'Beir	Charden durants, nore durants, Jones durants, Jones durants, Moure Bortents, Analysis Hartender, Brong Burg, Salar Charden, Sana Carlell, Byart Chareno, John Campbell, Carol Cardina, Jerring Carnon, Wei Hartender, Karlend Cardin, Salar Charden, Salar Charden, Jerring Carnon, Salar Charden, Jerring Carnon, Salar Charden, Jerring Carnon, Salar Charden, Jerring Carnon, Salar Charden, Jerring Carnon, Salar Charden, Salar Charden, Bartend Carnon, Charden Carle, Analy Carnon, Salar Charden, Salar Chard
A Carloon, Samuel Carnibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Gathleen Carter, Susan Cassidy, Thomas Cavare. Aggu Janet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, Ma Tode Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, Ma Tode Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Caster Tode Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Caster Tode Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Caster the, Akaterini Gekas, Larry George, Anthony Gerran, Swarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Gilbody, Judith Giri, Leonare che, Akaterini Gekas, Larry George, Anthony Gerran, Swarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Cilbody, Judith Giri, Leonare these, Eric Hicks, Basim Hilal, Serena Hill, Junius Hill, Timothy Hill, Ashlee Hill, Bryan Hirschon, Carl Hixon, Hant ThiHoang, Michael Hoar, Elaine ko, Shino Inouye, Jesse Ivers, ITI, John Jacanin, Peter James, Douglas Jankowski, Kurt Janson, Kristine Jaramillo, Greer Jattan, Amha Jember, Liyin n Kehry, Steven Kelly, Steven Kendall, Kristine Kepler, Janice Kern, Daniel Kim, Yune Kim, Martin King, Timothy Kirchner, Terry Klinker, William Klo x, Leilani Larson, Cleofe Lastrella, Chevelle Lattimore, David Laube, Eric Lauzon, Jeanne Levie, Luann Lee, Misun Lee, Brana Lee, Bryan Leigh, Justi y, Kert Lowery, Katherine Loya-Dial, Jim Lunsford, William Lynch, Robert MacGillis, Lydia Madura, Jossector Magana, Marijo Magill, Patrick Mains, Da McCluskey, Kelly McConnell, David McKinley, Karen McLachlan, Lisa McLain, Sonia Medder, Launn Lee, Mornic, Merie, Merrit, Lisal toris, Ayasa Noerga, Nary Helena O'Beir	Christian Barran
A Carloon, Samuel Carnibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Cathleen Carter, Susan Cassidy, Thomas Cavare. Ageu Janet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, Mar Sint Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, Mar Sint De Weerd, Katherine Deane-Bousum, Jami DeBrango-Palumbo, Kathleen DeKoker, Allan Delacruz, Hugo Delgadillo, Charles Demeree, Freder Jann Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Cas Eng Ty Fields, Susette Fino, Jonathan Fitchett, Kenneth Fite, Edith Fite, Joyce Fleming, Geraldine Fontillas, Sharlene Forbes, Helen Forrester, Li cox Ch ch. Alkaterini Gekas, Larry George, Anthony Gerran, Swarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Cillbody, Judith Giri, Leonar Man Acker, Dennis Hallissey, Leslie Halkey, Kenneth Hamilton, Nabil Hanna, John Hanson, Kandasamy Hariharan, Steven Harries, Jonathan Hartley, - h Hess, Eric Hicks, Basim Hilal, Serena Hill, Junius Hill, Timothy Hill, Ashlee Hill, Bryan Hirschon, Carl Hixon, Hant ThiHoang, Michael Hoar, Elaine Ko, Shino Inouye, Jesse Ivers, III, John Jacanin, Peter Jamee, Douglas Jankowski, Kurt Janson, Kristine Jaramillo, Greer Jattan, Amha Jember, Liyin n Kehry, Steven Kelly, Steven Kendall, Kristine Kepler, Janice Kern, Daniel Kim, Yume Kim, Martin King, Timothy Kirchner, Terry Klinker, William Klo x, Lellani Larson, Cleofe Lastrella, Chevelle Lattimore, David Laube, Eric Lauzon, Jeanne Lavie, Luann Lee, Misun Lee, Dana Lee, Bryan Leigh, Justi Y, Kert Lowery, Katherine Loya-Dial, Jin Lunsford, William Lynch, Robert MacGillis, Lydia Madura, Josuector Magana, Marijo Magill, Patrick Mains, Da McCluskey, Kelly McConnell, David McKinley, Karen McLachlan, Lisa McLain, Sonia Medder, Launn teeke, Victor Meisenhelder, James Merritt, Elial onris, Ayasa Noorgi, Kary Hele	Charden durants, nore durants, Jones durants, Jones durants, Moure Bortents, Analysis Hartender, Brong Burg, Salar Charden, Sana Carlell, Byart Chareno, John Campbell, Carol Cardina, Jerring Carnon, Wei Hartender, Karlend Cardin, Salar Charden, Salar Charden, Jerring Carnon, Salar Charden, Jerring Carnon, Salar Charden, Jerring Carnon, Salar Charden, Jerring Carnon, Salar Charden, Jerring Carnon, Salar Charden, Salar Charden, Bartend Carnon, Charden Carle, Analy Carnon, Salar Charden, Salar Chard
A Cardoon, Samuel Carnibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Cathleen Carter, Susan Cassidy, Thomas Cavare. Ageu Janet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, Mar Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Eikhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Case Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Eikhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Case Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Eikhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Case Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Eikhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Case Ch, Alkaterini Gekas, Larry George, Anthony Gerran, Swarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Cilbody, Judith Giri, Leonare che, Alkaterini Gekas, Larry George, Anthony Gerran, Swarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Cilbody, Judith Giri, Leonare che, Alkaterini Gekas, Larry George, Anthony Gerran, Swarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Cilbody, Judith Giri, Leonare che, Shino Inouge, Jasse Ivers, III, John Jacanin, Peter James, Douglas Jankowski, Kurt Janson, Kristine Jaramillo, Greer Jattan, Amha Jember, Liyin n Kehry, Steven Kelly, Steven Kendall, Kristine Kepler, Janice Kern, Daniel Kim, Yume Kim, Martin King, Timothy Kirchner, Terry Klinker, William Klo x, Leilani Larson, Cleofe Lastrella, Chevelle Lattimore, David Laube, Eric Lauzon, Jeanne Lavie, Luann Lee, Misun Lee, Dana Lee, Bryan Leigh, Justi y Kert Lowery, Katherine Loya-Dial, Jin Lunsford, William Lynch, Robert MacGillis, Lydia Madura, Josuector Magana, Marijo Magill, Patrick Mains, Da McCluskey, Kelly McConnell, David McKinley, Karen McLachlan, Lisa McLain, Sonia Medders, Launn Lee, Misun Lee, Dana Lee, Bryan Leigh, Justi ge Pena, Lidda Penreb, Neather	Charden behaves behave
A Cardon, Samuel Carnibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Cathleen Carter, Susan Cassidy, Thomas Cavare. Ageu J anet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connoers, Dennis Cooney, Mar Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Elington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Caster Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Elington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Caster Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Elington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Caster Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Elington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Caster Ch, Aikaterini Gekas, Larry George, Anthony Gerran, Svarnalata Ghanta, Brian Giambrone, Jack Giese, Catherine Gilbody, Judith Giri, Leonare dian acker, Dennis Hallissey, Leslie Halsey, Kenneth Hamilton, Nabil Hanna, John Hanson, Kandasamy Hariharan, Steven Harries, Jonathan Hartley, . h Hess, Eric Hicks, Basim Hilal, Serena Hill, Junius Hill, Timothy Hill, Ashke Hill, Byan Hirschon, Carl Hixon, Hanh ThiHoang, Michael Hoar, Elaine io, Shino Inouye, Jasse Ivers, III, John Jacarin, Peter James, Douglas Jankowski, Kurt Janson, Kristine Jaramillo, Greer Jattan, Amha Jember, Liyin n Kehry, Steven Keily, Steven Kendall, Kristine Kepler, Janice Kern, Dariel Kim, Yune Kim, Martin King, Timothy Kirchner, Terry Klinker, William Klo x, Leilani Larson, Cleofe Lastrella, Chevelle Lattimore, David Laube, Fric Lauzon, Jeanne LaVoie, Laann Lee, Misun Lee, Dana Lee, Byan Leigh, Jasti y, Kent Lewery, Katherine Loya-Dial. Jin Lunsford, William Lynch, Robert Hatchillis, Lydal Madura, Josuector Magana, Marijo Magill, Patrick Mains, Da McCluskey, Kelly McConnell, David McKinley, Karen McLachlan, Lisa McLain, Sonia Medder, Lamon Meeke, Victor Meisenhelder, James Merritt, Elisal y, Margue	Charden bege
A Cardon, Samuel Carnibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Cathleen Carter, Susan Cassidy, Thomas Cavare. Ageu J anet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connoers, Dennis Cooney, Mar Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Elington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Caster Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Elington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Caster Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Elington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Caster Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Elington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Caster Ch, Aikaterini Gekas, Larry George, Anthony Gerran, Svarnalata Ghanta, Brian Giambrone, Jack Giese, Catherine Gilbody, Judith Giri, Leonare dian acker, Dennis Hallissey, Leslie Halsey, Kenneth Hamilton, Nabil Hanna, John Hanson, Kandasamy Hariharan, Steven Harries, Jonathan Hartley, . h Hess, Eric Hicks, Basim Hilal, Serena Hill, Junius Hill, Timothy Hill, Ashke Hill, Byan Hirschon, Carl Hixon, Hanh ThiHoang, Michael Hoar, Elaine io, Shino Inouye, Jasse Ivers, III, John Jacarin, Peter James, Douglas Jankowski, Kurt Janson, Kristine Jaramillo, Greer Jattan, Amha Jember, Liyin n Kehry, Steven Keily, Steven Kendall, Kristine Kepler, Janice Kern, Dariel Kim, Yune Kim, Martin King, Timothy Kirchner, Terry Klinker, William Klo x, Leilani Larson, Cleofe Lastrella, Chevelle Lattimore, David Laube, Fric Lauzon, Jeanne LaVoie, Laann Lee, Misun Lee, Dana Lee, Byan Leigh, Jasti y, Kent Lewery, Katherine Loya-Dial. Jin Lunsford, William Lynch, Robert Hatchillis, Lydal Madura, Josuector Magana, Marijo Magill, Patrick Mains, Da McCluskey, Kelly McConnell, David McKinley, Karen McLachlan, Lisa McLain, Sonia Medder, Lamon Meeke, Victor Meisenhelder, James Merritt, Elisal y, Margue	Charden behaves behave
A Cardon, Samuel Carnibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Cathleen Carter, Susan Cassidy, Thomas Cavare A get J anet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, Mar See Weerd, Katherine Deane-Bousum, Jami DeBrango-Palumbo, Kathleen DeKoker, Allan Delacruz, Hugo Delgadillo, Charles Demeree, Freder Jamn Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Land Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Land try Fields, Susatte Fino, Jonatham Fitchett, Kenneth Fite, Edith Fite, Joyce Reming, Geraldine Fontillas, Sharlene Forbes, Helen Forrester, Land ch, Alkaterini Gekas, Larry George, Anthony Gerran, Swarnalata Ghanta, Brian Giambrone, Jack Giese, Catherine Gilbody, Judith Giri, Leonart Man acker, Dennis Hallissey, Leslie Haleey, Kenneth Hamilton, Nabil Hanna, John Hanson, Kandasamy Hartharan, Steven Harries, Jonathan Hartley, . h Hess, Eric Hicks, Basim Hilal, Serena Hill, Junius Hill, Timothy Hill, Ashlee Hill, Byan Hirschon, Carl Hixon, Hanh ThiHoang, Michael Hoar, Elaine ko, Shino Inouye, Jesse Ivers, III, John Jacanin, Peter James, Douglas Jankowski, Kurt Jamson, Kristine Jaramillo, Greer Jattan, Amha Jember, Lyin n Kehry, Steven Kelly, Steven Kendall, Kristine Kepler, Janice Kern, Daniel Kim, Yune Kim, Martin King, Timothy Kirchner, Terry Klinker, William Klo x, Lellani Larson, Cleofe Lastrella, Chevelle Lattimore, David Laube, Eric Lauzon, Jeanne LaVoie, Luann Lee, Misun Lee, Bana Lee, Bryan Leigh, Jasti y, Marguerite Montgomery, Erika Mora, Anthony Morandi, Ronald Morena, Carol Morgan, Noralee Morris, Ameria Morris, Lyle Mowery, Javier Morzo Jamonso, Yany Helema O'Beirne, Loretta O'Neil, Kevin O'Keilly, Scott Obenshain, Brian Oehler, Teresa Olejnik, Jessica Oloon, Jaen O'Esson, Kanger, Branden, Wincent Reardon, Mi	Charden bege
A Cardoon, Samuel Carnibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Gathleen Carter, Susan Cassidy, Thomas Coarae. Age Janet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, Ma Sinte Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, Ma Sinte Clark, Statherine Deane-Bousum, Jami DeBrango-Palumbo, Kathleen DeKoker, Allan Delacruz, Hugo Delgadillo, Charles Demeree, Freder Jenn Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, L. a Eng rhy Fields, Susette Fino, Jonathan Fitchett, Kenneth Fite, Edith Fite, Joyce Fleming, Geraldine Fontillas, Sharleme Forbes, Helen Forrester, Li cov, Ch ch, Aikaterini Gekas, Larry George, Anthony Gerran, Swarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Gilbody, Judith Giri, Leonar eker, Dennis Hallissey, Leslie Halesy, Kenneth Hamitton, Nabil Hanna, John Hanson, Kandasamy Hariharan, Steven Harries, Jonathan Hartley, . h Hess, Eric Hicks, Basim Hilal, Serena Hill, Junius Hill, Timothy Hill, Ashlee Hill, Bryan Hirschon, Carl Hixon, Hanh ThiHoang, Michael Hoar, Elaine io, Shino Inouye, Jesse Ivers, III, John Jacanin, Peter Jamee, Douglas Jankowski, Kurt Janson, Kristine Jaramillo, Greer Jattan, Amha Jember, Lipin n Kehry, Steven Kelly, Steven Kendall, Kristine Kepler, Janice Kern, Daniel Kim, Yune Kim, Martin King, Timothy Kirchner, Terry Klinker, William Klo x, Lelani Larson, Geofe Lastrella, Chevelle Lattimore, David Laube, Eric Lauzon, Jeanne LaYoie, Luann Lee, Misun Lee, Dana Lee, Bran Leigh, Jasti U, Kent Lowery, Katherine Loya-Dial, Jin Lunsford, William Lynch, Robert MacGillis, Lydia Madura, Josuector Magana, Marijo Magill, Patrick Mains, Da McClunkey, Kally McConnell, David McKinley, Karen McLachlan, Lisa McLain, Sonia Medder, Lamont Meeks, Victor Meisenhelder, James Merritt, Elizal y Marguerite Montgomery, Erika Mora,	Carbon construction of the structure based and
A Cardoon, Samuel Carnibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Gathleen Carter, Susan Cassidy, Thomas Coarae. Age Janet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, Ma Sinte Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, Ma Sinte Clark, Statherine Deane-Bousum, Jami DeBrango-Palumbo, Kathleen DeKoker, Allan Delacruz, Hugo Delgadillo, Charles Demeree, Freder Jenn Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, L. a Eng rhy Fields, Susette Fino, Jonathan Fitchett, Kenneth Fite, Edith Fite, Joyce Fleming, Geraldine Fontillas, Sharleme Forbes, Helen Forrester, Li cov, Ch ch, Aikaterini Gekas, Larry George, Anthony Gerran, Swarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Gilbody, Judith Giri, Leonar eker, Dennis Hallissey, Leslie Halesy, Kenneth Hamitton, Nabil Hanna, John Hanson, Kandasamy Hariharan, Steven Harries, Jonathan Hartley, . h Hess, Eric Hicks, Basim Hilal, Serena Hill, Junius Hill, Timothy Hill, Ashlee Hill, Bryan Hirschon, Carl Hixon, Hanh ThiHoang, Michael Hoar, Elaine io, Shino Inouye, Jesse Ivers, III, John Jacanin, Peter Jamee, Douglas Jankowski, Kurt Janson, Kristine Jaramillo, Greer Jattan, Amha Jember, Lipin n Kehry, Steven Kelly, Steven Kendall, Kristine Kepler, Janice Kern, Daniel Kim, Yune Kim, Martin King, Timothy Kirchner, Terry Klinker, William Klo x, Lelani Larson, Geofe Lastrella, Chevelle Lattimore, David Laube, Eric Lauzon, Jeanne LaYoie, Luann Lee, Misun Lee, Dana Lee, Bran Leigh, Jasti U, Kent Lowery, Katherine Loya-Dial, Jin Lunsford, William Lynch, Robert MacGillis, Lydia Madura, Josuector Magana, Marijo Magill, Patrick Mains, Da McClunkey, Kally McConnell, David McKinley, Karen McLachlan, Lisa McLain, Sonia Medder, Lamont Meeks, Victor Meisenhelder, James Merritt, Elizal y Marguerite Montgomery, Erika Mora,	 Charlen de lace de la
A Carloon, Samuel Carnibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Cathleen Carter, Susan Cassidy, Thomas Course, Agu Janet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, Ma Sint Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, Ma See Weerd, Katherine Deane-Bousum, Jami DeBrango-Palumbo, Kathleen DeKoker, Allan Delacruz, Hugo Delgadillo, Charles Demeree, Freder Jond Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Car, Ch Ch. Akaterini Gekas, Larry George, Anthony Gerran, Swarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Gilbody, Judith Giri, Leonara eker, Dennis Hallissey, Leslie Haleey, Kenneth Hamilton, Nabil Hanna, John Hanson, Kandasamy Hartharan, Steven Harries, Jonathan Hartley, - h Hess, Eric Hicks, Basim Hilal, Serena Hill, Junius Hill, Timothy Hill, Ashlee Hill, Bryan Hirschon, Carl Hixon, Hant ThiHoang, Michael Hoar, Elaine ko, Shino Inouye, Jesse Ivers, ITI, John Jacanin, Peter Jamee, Douglas Jankowski, Kurt Janson, Kristine Jaramillo, Greer Jattan, Amha Jember, Liyin n Kehry, Steven Kelly, Steven Kendall, Kristine Kepler, Janice Kern, Daniel Kim, Yune Kim, Martin King, Timothy Kirchner, Terry Klinker, William Klo x, Leilani Larson, Cleofe Lastrella, Chevelle Lattimore, David Laube, Eric Lauzon, Jeanne Levie, Luann Lee, Misun Lee, Dana Lee, Bryan Leigh, Jasti Y, Marguerite Mortgomery, Erika Mora, Anthony Morandi, Ronald Morena, Carol Morgan, Noralee Morris, America Morris, Lyle Mowery, Javier Kator, Katherine Loya-Dial, Jin Lunsford, William Lynch, Robert MacGillis, Lydia Madura, Josuector Magana, Marijo Magill, Patrick Mains, Da McCluskey, Kelly McConnell, David McKinley, Karen McLachlan, Lisa McLain, Sonia Medder, Lamont Meeks, Victor Meisenhelder, James Merritt, Elisal Lin Friellin Schneiger, Erak Mora, Anthony Morandi, Ronald Morena, Ca	Carbon construction of the structure based and
A Carloon, Samuel Carnibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Cathleen Carter, Susan Cassidy, Thomas Coure, Agu Janet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, Ma Sint De Weerd, Katherine Deane-Bousum, Jami DeBrango-Palumbo, Kathleen DeKoker, Allan Delacruz, Hugo Delgadillo, Charles Demeree, Freder Jann Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Cas, Ch Ch, Alkaterini Gekas, Larry George, Anthony Gerran, Swarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Cillbody, Judith Giri, Leonar Cas, Ch, Alkaterini Gekas, Larry George, Anthony Gerran, Swarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Cillbody, Judith Giri, Leonar Cas, Ch, Alkaterini Gekas, Larry George, Anthony Gerran, Swarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Cillbody, Judith Giri, Leonar Cas, Ch, Alkaterini Gekas, Larry George, Anthony Gerran, Swarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Cillbody, Judith Giri, Leonar Cas, Ch, Baster Hilds, Serena Hill, Junius Hill, Timothy Hill, Ashlee Hill, Bryan Hirschon, Carl Hixon, Hant ThiHoang, Michael Hoar, Elaine Ko, Shino Inouye, Jesse Ivers, ITI, John Jacanin, Peter Jamee, Douglas Jankowski, Kurt Janson, Kristine Jaramillo, Greer Jattan, Amha Jember, Liyin n Kehry, Steven Kelly, Steven Kendall, Kristine Kepler, Janice Kern, Daniel Kim, Yune Kim, Martin King, Timothy Kirchner, Terry Klinker, William Klo x, Lellani Larson, Cleofe Lastrella, Chevelle Lattimore, David Laube, Eric Lauzon, Jeanne LeVie, Luann Lee, Misun Lee, Dana Lee, Boyan Leigh, Justi W, Kert Lowery, Katherine Loya-Dial, Jin Lunsford, William Lynch, Robett MacGillis, Lydia Madura, Josuector Magana, Marijo Magill, Patrick Mains, Da McCluskey, Kelly McConnell, David McKinley, Karen McLachlan, Lisa McLain, Sonia Medder, Luann Lewe, Nicotor Meisenhelder, James Meerritt, Elisal Gris, Aysan Novej, Nary Helena O'Beir	
A Cardon, Samuel Carnibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Cathleen Carter, Susan Cassidy, Thomas Courp. A guit J anet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connoers, Dennis Cooney, Mar Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Eikhayat, Cynthia Eliington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Caster Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Eikhayat, Cynthia Eliington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Caster Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Eikhayat, Cynthia Eliington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Caster Ch, Aikaterini Gekas, Larry George, Anthony Gerran, Svarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Cillbody, Judith Giri, Leonar Gan cher, Dennis Hallissey, Leslie Halsey, Kenneth Hamilton, Nabil Hanna, John Hanson, Kandasamy Hartharan, Steven Harries, Jonathan Hartley, . h Hess, Eric Hicks, Basim Hilal, Serena Hill, Junius Hill, Timothy Hill, Ashke Hill, Byan Hirschon, Carl Hixon, Hanh ThiHoang, Michael Hoar, Elaine is, Shino Inouge, Jasse Ivers, III, John Jacarin, Peter James, Douglas Jankowski, Kurt Janson, Kristine Jaramillo, Greer Jattan, Amha Jember, Liyin n Kehry, Steven Kelly, Steven Kendall, Kristine Kepler, Janice Kern, Daniel Kim, Yune Kim, Martin King, Timothy Kirchner, Terry Klinker, William Klo x, Leilani Jarson, Cleofe Lastrella, Chevelle Lattimore, Bord Laube, Eric Lauzon, Jeanne LaVole, Luann Lee, Misun Lee, Dana Lee, Byan Leigh, Jauti y, Kert Lowery, Katherine Loya-Dial, Jin Lunsford, William Lynch, Robert MacGillis, Iydia Madura, Josaector Magana, Marijo Magill, Patrick Mains, Da McCluskey, Kelly McConnell, David McKinley, Karen McLachlan, Lisa McLain, Sonia Medders, Launn Meeks, Victor Meisenhelder, James Merritt, Elisal Pars, Ajasa Norgi, Mary Helena O'Beime, Loretta O'Neil, Kevin O'Reilly, Sotit Obenshain, Brian Oehler, Teresa Olejnik, Jeassia Olson, Jean Otson, J Markh	
A Cardon, Samuel Carnibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Cathleen Carter, Susan Cassidy, Thomas Courp. A guit J anet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connoers, Dennis Cooney, Mar Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Eikhayat, Cynthia Eliington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Caster Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Eikhayat, Cynthia Eliington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Caster Todd Edgington, Mikel Edwards, Emelyn Eldredge, Amr Eikhayat, Cynthia Eliington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Caster Ch, Aikaterini Gekas, Larry George, Anthony Gerran, Svarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Cillbody, Judith Giri, Leonar Gan cher, Dennis Hallissey, Leslie Halsey, Kenneth Hamilton, Nabil Hanna, John Hanson, Kandasamy Hartharan, Steven Harries, Jonathan Hartley, . h Hess, Eric Hicks, Basim Hilal, Serena Hill, Junius Hill, Timothy Hill, Ashke Hill, Byan Hirschon, Carl Hixon, Hanh ThiHoang, Michael Hoar, Elaine is, Shino Inouge, Jasse Ivers, III, John Jacarin, Peter James, Douglas Jankowski, Kurt Janson, Kristine Jaramillo, Greer Jattan, Amha Jember, Liyin n Kehry, Steven Kelly, Steven Kendall, Kristine Kepler, Janice Kern, Daniel Kim, Yune Kim, Martin King, Timothy Kirchner, Terry Klinker, William Klo x, Leilani Jarson, Cleofe Lastrella, Chevelle Lattimore, Bord Laube, Eric Lauzon, Jeanne LaVole, Luann Lee, Misun Lee, Dana Lee, Byan Leigh, Jauti y, Kert Lowery, Katherine Loya-Dial, Jin Lunsford, William Lynch, Robert MacGillis, Iydia Madura, Josaector Magana, Marijo Magill, Patrick Mains, Da McCluskey, Kelly McConnell, David McKinley, Karen McLachlan, Lisa McLain, Sonia Medders, Launn Meeks, Victor Meisenhelder, James Merritt, Elisal Pars, Ajasa Norgi, Mary Helena O'Beime, Loretta O'Neil, Kevin O'Reilly, Sotit Obenshain, Brian Oehler, Teresa Olejnik, Jeassia Olson, Jean Otson, J Markh	
A Cardoon, Samuel Carnibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Cathleen Carter, Susan Cassidy, Thomas Cavare. Ageu Janet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, Mark De Weerd, Katherine Deane-Bousum, Jami DeBrango-Palumbo, Kathleen DeKoker, Allan Delacruz, Hugo Delgadillo, Charles Demeree, Freder Jann Todd Edgington, Nikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Cas, Ch Ch, Alkaterini Gekas, Larry George, Anthony Gerran, Swarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Gilbody, Judith Giri, Leonara eker, Dennis Hallissey, Leslie Halkey, Kenneth Hamilton, Nabil Hanna, John Hanson, Kandasamy Hartharan, Steven Harries, Jonathan Hartley, - h Hess, Eric Hicks, Basim Hilal, Serena Hill, Junius Hill, Timothy Hill, Ashlee Hill, Bryan Hirschon, Carl Hixon, Hanh ThiHoang, Michael Hoar, Elaine Ko, Shino Inouye, Jesse Ivers, ITI, John Jacanin, Peter Jamee, Douglas Jankowski, Kurt Janson, Kristine Jaramillo, Greer Jattan, Amha Jember, Liyin n Kehry, Steven Kelly, Steven Kendall, Kristine Kopler, Janice Kern, Daniel Kim, Yune Kim, Martin King, Timothy Kirchner, Terry Klinker, William Klo x, Leilani Larson, Cleofe Lastrella, Chevelle Lattimore, David Laube, Eric Lauzon, Jeanne Levie, Luann Lee, Misun Lee, Dana Lee, Bryan Leigh, Justi y Marguerite Mortgomery, Erika Mora, Anthony Morandi, Ronald Morena, Carol Morgan, Noralee Morris, America Morris, Lyle Mowery, Jawier Mozo Ji Geris, Agusa Wong, Mary Helena O'Beirne, Loretta O'Neil, Kevin O'Keilly, Scott Obershain, Brian Oehler, Terea Olejnik, Jessica Olson, Jaen Olson, J ea Pena, Lidia Reome, Nany Helena O'Beirne, Loretta O'Neil, Kevin O'Keilly, Scott Obershain, Brian Oehler, Terea Olejnik, Jessica Olson, Jaen Olson, J et Hillip Schneiger, Jacqueline Schoppe, Carolynn Schoppe, Christina Schwalle, Mary Schwalen, Lois Schwartz, Heather Scott, Neno Segura, Adam Oral Simmors, Juzie Sims, Adnam S	
A Cardoon, Samuel Carnibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Cathleen Carter, Susan Cassidy, Thomas Cavare. Ageu Janet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, Mark De Weerd, Katherine Deane-Bousum, Jami DeBrango-Palumbo, Kathleen DeKoker, Allan Delacruz, Hugo Delgadillo, Charles Demeree, Freder Jann Todd Edgington, Nikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Cas, Ch Ch, Alkaterini Gekas, Larry George, Anthony Gerran, Swarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Gilbody, Judith Giri, Leonare Car, Akaterini Gekas, Larry George, Anthony Gerran, Swarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Gilbody, Judith Giri, Leonare Car, Akaterini Gekas, Larry George, Anthony Gerran, Swarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Gilbody, Judith Giri, Leonare Car, Akaterini Gekas, Larry George, Anthony Gerran, Swarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Gilbody, Judith Giri, Leonare Car, Akaterini Gekas, Larry George, Anthony Gerran, Swarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Gilbody, Judith Giri, Leonare Cae, Shane Thousye, Jasse Ivers, III, John Jacanin, Peter Jamee, Douglas Jankowski, Kurt Janson, Kristine Jaramillo, Greer Jattan, Amha Jember, Liyin n Kehry, Steven Kelly, Steven Kendall, Kristine Kopler, Janice Kern, Daniel Kim, Yune Kim, Martin King, Timothy Kirchner, Terry Klinker, William Klo x, Leilani Larson, Cleofe Lastrella, Chevelle Lattimore, David Laube, Eric Lauzon, Jeanne Levleie, Luann Lee, Misun Lee, Dana Lee, Bryan Leigh, Justi Y, Kert Lowery, Katherine Loya-Dial, Jin Lunsford, William Lynch, Robert MacGillis, Lydia Madura, Josuector Magana, Marijo Magill, Patrick Mains, Da McCluskey, Kelly McConnell, David McKinley, Karen McLachlan, Lisa McLain, Sonia Medders, Launot Meeks, Victor Meisenhelder, James Meeritt, Elisal Grin, Ayasa Noong, Mary Helena O'Beirne, Loretta	
A Cardoon, Samuel Carnibucci, Matthew Carpenter, Scott Carrier, David Carrillo, Cathleen Carter, Susan Cassidy, Thomas Cavare. Ageu Janet Clark, Joyce Cleary, Thomas Clough, Gregory Cole, Francisco Colon, Barbara Compeau, Lynn Conley, Brian Connors, Dennis Cooney, Mark De Weerd, Katherine Deane-Bousum, Jami DeBrango-Palumbo, Kathleen DeKoker, Allan Delacruz, Hugo Delgadillo, Charles Demeree, Freder Jann Todd Edgington, Nikel Edwards, Emelyn Eldredge, Amr Elkhayat, Cynthia Ellington, Roselle Ellison, Dirk Ellison, Mark Ellison, Paul Elpers, Cas, Ch Ch, Alkaterini Gekas, Larry George, Anthony Gerran, Swarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Gilbody, Judith Giri, Leonare Car, Akaterini Gekas, Larry George, Anthony Gerran, Swarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Gilbody, Judith Giri, Leonare Car, Akaterini Gekas, Larry George, Anthony Gerran, Swarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Gilbody, Judith Giri, Leonare Car, Akaterini Gekas, Larry George, Anthony Gerran, Swarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Gilbody, Judith Giri, Leonare Car, Akaterini Gekas, Larry George, Anthony Gerran, Swarnalata Chanta, Brian Giambrone, Jack Giese, Catherine Gilbody, Judith Giri, Leonare Cae, Shane Thousye, Jasse Ivers, III, John Jacanin, Peter Jamee, Douglas Jankowski, Kurt Janson, Kristine Jaramillo, Greer Jattan, Amha Jember, Liyin n Kehry, Steven Kelly, Steven Kendall, Kristine Kopler, Janice Kern, Daniel Kim, Yune Kim, Martin King, Timothy Kirchner, Terry Klinker, William Klo x, Leilani Larson, Cleofe Lastrella, Chevelle Lattimore, David Laube, Eric Lauzon, Jeanne Levleie, Luann Lee, Misun Lee, Dana Lee, Bryan Leigh, Justi Y, Kert Lowery, Katherine Loya-Dial, Jin Lunsford, William Lynch, Robert MacGillis, Lydia Madura, Josuector Magana, Marijo Magill, Patrick Mains, Da McCluskey, Kelly McConnell, David McKinley, Karen McLachlan, Lisa McLain, Sonia Medders, Launot Meeks, Victor Meisenhelder, James Meeritt, Elisal Grin, Ayasa Noong, Mary Helena O'Beirne, Loretta	<text></text>



PRATIK MULTANI, M.D., Director, Medical Affairs

٨

Pratik Multani joined IDEC from Massachusetts General Hospital where he was an investigator in the Bone Marrow Transplant Unit. Today he heads the group at IDEC that is exploring Zevalin's use with other therapies in the treatment of NHL and other cancers. "At IDEC, I've been able to help design and implement large multicenter clinical trials in collaboration with thought leaders in the field of lymphoma," he says. "In academia, such an opportunity would come only after many years. IDEC is making a big difference in the treatment of lymphoma, and I am excited to be part of this important work."

SUSAN SCHMITT, Manager of Clinical Immunology Susan Schmitt manages the IDEC lab that analyzes clinical samples and gathers patient data to support regulatory submissions for IDEC's products. She also leads a half-million-dollar information management project which involves integrating input from IDEC departments, including biometrics, information technology, clinical trials management, clinical research and the preclinical research group. Outside the lab, Susan has been a standard setter as well, helping IDEC raise a record 21,000 pounds of food for the San Diego Food Bank. "IDEC has a strong commitment to the community as well as its employees, and I'm proud to be a part of that effort." **AMY SCHEIR,** *Clinical Documentation Specialist* Amy Scheir was quickly invited to join IDEC after first working as a temporary employee. Today, despite a hearing impairment, Amy is a valued member of the group that prepares documentation, graphics and slides to meet clinical and regulatory needs. She played an integral role in preparing the ODAC presentation on Zevalin, working around the clock to ensure that the 600 back-up slides were correct and ready for that meeting. "IDEC has been like a family for me," Amy says. "I feel good knowing that my contribution is valued and helping to make a difference in the world."

JOHANNES ROEBERS, Senior Director and Project Manager, NIMO Johannes Roebers has overseen construction of a pharmaceutical manufacturing plant before, but always as a facility redesign or add-on, never from the ground up. "Joining IDEC has given me the opportunity to lead the design and construction of a large manufacturing facility from conception to reality. It is an awesome challenge, but it gives us the chance to build the facility 'right' from the start." Johannes appreciates the support of IDEC management and the freedom he feels to express his own ideas. "I feel truly empowered to help the company do this job in the best way that we can."

32

IDEC 2001 ANNUAL REPORT



330 \$ 38,712	36,118					\$ 1: 179,95 106,42	8 \$176,448 6 57	\$	(37) \$ (99,353)	(83,815) 80,679 21,4	\$,478	92,614 (15,538) (15 300 2,478 228 (37) \$ (83,815) \$,538)	(15,444) 1,340 1 40,242	20	3,5 \$ 92,614	08 3,509 245 18 (15,538)	3176,448 164,282 (15,538)	\$ (15,444) 1,340
1 2,230 \$ 159,978												- 12,672 3,508 3,509 245 179,956 57 21,478 228				40,242		(36,712 (36,712) 80,879 21,478 20	
330 \$ 38,712												$\begin{array}{c} 1 & (77,875) \\ \begin{array}{c} 2,230 \\ 92,914 & (15,538) \\ 1,4376 \\ 195,218 \\ 3 \\ 195,218 \\ 3 \\ 5 \\ 5 \\ 195,218 \\ 3 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5$					106,428 08 3,509 245 42,672 \$	 184,282 159,978	 \$
1 2,230 \$ 159,978												42,672 \$					Ŷ		
												330 \$ 36,118 (37) \$ (83,815) \$ 1 3,508 3,509 245					18 (15,538) 	\$178,448 (15,538) 38,712	\$ (15,444) 1,340 19
330 \$ 38,712 1 2,230												92,61, 170,958,8) 57 (15,558) 21,478 228 228 1 (77,875)				40,242	06 ⁽⁹⁹ ,509)245	80,679 21,478 20 184,282	184,282
1 2,230 3 159,978												2,230 14,300 218 \$ 195,218 \$ (543)\$				14,308 (34,718)	42,672	(34,718) \$21 159,978	\$
170 A												330 \$ 36,118 (37) \$ (83,815) \$				\$ 92,614	18 06 ^(15,538) 245	\$176,448 (15,538)	ş (15,444) 1,340
530 \$ 38,712 1 2,230												(37) \$ (15,538) \$ (15 21,478 3,508,500 245 21,478 57						164,252 80,679 21,478	
2,230 9 159,978												21,478 228 1 (77,875) 2,230 1 14,309 218 \$				40,242	106,428	(34,718) \$ 21	184,282 \$
330 \$ 38,712																^(34,718) 3,5	08 3,509 245	159,978 184,282	Ť
- 38,712 1 2,230 159,978																			
												330 \$ 36,118 (37) \$ (83,815) \$				\$ 92,614	18	\$176,448 (15,538)	\$ (15,444) 1,340
330 \$ 38,712 1 2 230												92,614 (15,538) 3,508 3,509 245 2178,9856 228 21,478 228					(19,358) (99,353) (99,353)	(10,500) 38,712 160,252 20 20	
2,230 3 159,978												$-\frac{1}{2,230}$ $\frac{1}{20}$ $\frac{(77,875)}{2}$ 3,508				14,308	106,428		
												14,309 218 \$ 195,2 <mark>1843</mark> \$ (543)\$ \$				(34,718)	42,672	\$21 159,978	Ş
330 \$ 38,712						(83 ₀ 815) 1 80,679 ₇ 8,96	8 \$ 9 3193448 5,538) 878 21, 67 8 228			44) (66,625) 1 40,26,679 21,		330 \$ 36,118 627,61\$ (15,633,615) \$ 3,515 219,78 179,956 57				\$ 92,614 _{3,5}	18 08 ^(15,538) 245 (99,353)	\$176,448 (15,538) 38,732 163,252 80,079 21,478	\$ (15,444) 1,340 19
1 2,230 \$ 159,978												1/8,850 57 21,478547228 1 1 (77,875) 2,230 1				40,242	106,428	20 (36,718)	184,282
												2,200 1 14,309 218 \$ 305,1218 (5,538) (543) \$ (15					42,672 06 3,508 245	\$ 21 159,978	\$
330 \$ 38,712						1 (83,815) _{179,95} 80,6790014	8 \$176,448 6 \$ 92,614 <u>5</u> 1 5,538) 578 21,478 228					92,614 (15,538) (15 21,478 228 3,508 20					08 3,509 245		
2,230 \$ 159,978												300 \$ 543 7 36,118 \$ (37) \$ (83,815) \$ 1 3,508 3,509 245					18 (15,538)	(34,718) \$176,448 (15,538) 38,712	\$ (15,444) 1,340 19
330 9						;	8 \$176,448					179,956 57				40,242	(99,353) 08 3,509 245	80,679 21,478	
38,712 1						/9,95 106,42								year of re	CORI			184,262	
2,230 3 159,978						14(93 8 ⁸¹⁵ 80,6) 1 21,4						34,309 218 3 3 505		BALANCE				8 21	8
	14,301 O U	106,428	fina	nci	a ^{14,309} e	218	ALLOWS U	JS T	o Pi	LAN AN	ND	BUILD IDI	e c 's	FUTURE ,	in pa	rtic	ULAI	a (
														RCH AND I					
330 \$ 38,712						(83 ₀ 815 80,6 178,96								G FACILITI					\$ (15,444) 1,340
1 2,230 3 159,978						108.42	\$42,672 \$	A AN	14,309	195,218 \$		1121 CAMPUS - 1792 56 57 21,478 228	2 1	ND ADD NE (34,718]195,218 \$	(543)	40,242	(99,353)	80,678, 1,478 (30,671, 1,478 20	
, 159,978																14,308	106,428		
												14,309 218 \$					42,672	3 21	\$

14,308 14,309 1212 9 -48,672 21 105,528 300 5457 80,112 9 148,009 105,528 9 300 5457 80,112 9 148,009 105,528 9 105,528 9 105,528 9 105,528 9 105,528 9 105,528 9 105,528 105,528 9 105,528 1	38,712 1				80,67902142578		40,242	21,476 228 20			× ·	184,282
1 1								1 3,508 3,		92,614		(34,718) \$176,448 (15,538) 38,712 80,679 21,47
1 1 5 5.0 5.7 0 10 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>22,478 (15,228)</td> <td></td> <td>40,2423,</td> <td>508 3,509 245 106,428</td> <td></td>								22,478 (15,228)		40,2423,	508 3,509 245 106,428	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$								14,309 218, \$ 42,872 195,218 \$ (543) \$			42,672	(84,718) 159,978
$ \left[\begin{array}{cccccccccccccccccccccccccccccccccccc$												
14,000								(37) \$ (83,815) \$ 1 3,508 3, 179,956 57		92,614		\$176,448 (15,538) 38,712 80,679 21,47
$ \begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$		14,308 H						3543) (77,875) 2,230 1 14,309 218 \$		14,308	106,428	 \$ 21 159,978
14,508 14,508 105,428 \$ (643) (64,718) 2 1 105,428 \$ 105,428 \$ 105,428 \$ (643) (64,718) 2 1 105,428 \$ 105,428 \$ (643) \$ (84,718) 2 1 105,428 \$ 105,428 \$ (643) \$ (84,718) 2 1 105,428 \$ 105,428 \$ 0 3,608 \$,509 \$46 164,488 3 105,488 40,648 20 3,608 \$,509 \$46 164,488 3 105,488 40,648 20 3,608 \$,509 \$46 164,488 3 105,488 40,648 20 3,608 \$,509 \$46 164,488 3 105,488 40,648 20 3,608 \$,509 \$46 164,288 105,488 577 \$ (63,71) \$ 92,414 [15,638] 21,477 20 3,508 \$,509 \$45 104,508 106,438 40,648 20 3,508 \$,509 \$45 104,508 106,518 106,528		D \$										
Image: Second second		14,308						(543) 330 \$ 36,118		\$	18	\$176,448
3 179,088 57 (09,053) 80,079 21,478 228 40,042 20 124,282 14,308 14,309 218 \$ 40,072 \$ 21 \$ 105,428 \$ (643) \$ (34,718) - 14,308 * 14,309 218 \$ 40,672 \$ 21 \$ 105,428 \$ (643) \$ (34,718) - 126,428 * - 40,672 \$ 21 \$ 105,428 \$ (643) \$ (34,718) - 126,428 57 \$ (37) \$ (26,679 21,478 228 (15,588) (15,444) 1,340 1 20 3,508 3,508 164,282 u 14,508 - 14,509 218 \$ - 42,672 \$ 21 \$ 105,218 \$ (643) \$ (34,718) \$ \$ 34,682 \$ \$ (34,718) \$ \$ \$ \$ <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>												
14,308 14,309 218 \$ 42,672 \$ 21 \$ 105,528 \$ (643) \$ (34,718) > - 156,568 \$ 176,448 \$ (37) \$ (35,615) \$ 95,614 (15,558) (15,538) (15,548) 20 3,508 3,508 245 106,428 - 14,309 218 \$ 42,672 \$ 21 \$ 105,518 \$ (643) \$ (34,718) u 14,508 - 14,309 218 \$ 42,672 \$ 21 \$ 105,518 \$ (643) \$ (34,718) u 14,508 - 14,309 218 \$ 42,672 \$ 21 \$ 105,518 \$ (643) \$ (34,718) u 14,308 - 14,309 218 \$ 42,672 \$ 21 \$ 105,518 \$ (643) \$ (34,718) u 14,308 - 14,672 \$ 21,478 28 105,518 \$ (54.8) (643) \$ (34,718) u 1759,688 57 180,679 \$ 21,478 28,614 (15,538) (15,588) (15,544) 1,540 \$ 1 20 3,508 3,508 245 184,882		Þ										
• 179,088 57 (00,055) 80,679 21,478 21,477 228 40,642 20 1.04,882 • 106,428 14,309 218 \$ 40,642 20 1.04,882 • 104,4308 14,309 218 \$ 40,642 20 1.04,882 • • 14,309 218 \$ 40,642 20 (64.3) \$ (34,718) • </td <td></td> <td>0^{14,308}</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>		0 ^{14,308}										
u 14,308 24,309 218 \$ 48,472 \$ 21 \$ 195,218 \$ (543) \$ (54,728) ≪ ✓ ✓ ✓ ✓ 18 \$176,448 \$ (577) \$ (55,815) \$ 92,814 (15,538) (15,538) (15,544) 1,340 1 \$ 3,508 3,509 245 \$ 1979,088 57 \$ (96,355) 80,479 21,478 21,478 228 40,242 20 \$ 184,282 \$ 106,428 \$ 20 \$ 184,282 \$ 106,428 \$ 20 \$ 184,282 \$ 106,428 \$ 20 \$ 184,282 \$ 106,428 \$ 20 \$ 184,282 \$ 106,428 \$ 20 \$ 184,282 \$ 106,428 \$ 20 \$ 184,282 \$ 106,428 \$ 20 \$ 184,282 \$ 106,428 \$ 20 \$ 184,282 \$ 106,428 \$ 20 \$ 184,282 \$ 106,428 \$ 20 \$ 184,282 \$ 106,428 \$ 20 \$ 184,282 \$ 106,428												

I D E C 2 O O I A N N U A L R E P O R T

selected financial data }

ł

The following tables show certain financial data with respect to our Company. The selected financial data should be read in conjunction with the consolidated financial statements and notes thereto. The full audited consolidated financial statements for 2001 can be found in IDEC's Form 10-K, as filed with the Securities and Exchange Commission.

	Years ended December 31,									
(In thousands, except per share amounts)		2001		2000		1999		1998		1997
Consolidated Statements of Operations Data:										
Revenues:										
Revenues from unconsolidated joint business	\$	251,428	\$1	32,782	\$	93,197	\$	53,813	\$	9,266
Contract revenues		9,899	:	15,400		10,806		14,846		11,840
License fees		11,350		6,500		14,000		18,300		23,500
Total revenues		272,677	l	54,682	נ	18,003		86,959		44,606
Operating costs and expenses:										
Manufacturing costs				2,134		14,277		19,602		18,875
Research and development		86,299		68,922		42,831		31,485		32,407
Selling, general and administrative		55,241		27,767		19,478		16,968		11,320
Total operating costs and expenses		141,540		98,823		76,586		68,055		62,602
Income (loss) from operations		131,137		55,859		41,417		18,904		(17,996)
Interest income, net		30,467		13,488		4,189		2,996		2,572
Income (loss) before income tax provision		161,604		69,347		45,606		21,900		(15,424)
Income tax provision		59,945	:	11,939		2,449		422		114
Income (loss) before cumulative effect of										
accounting change		101,659		57,408		43,157		21,478		(15,538)
Cumulative effect of accounting change,										
net of income tax benefit of \$481				(9,263)						
Net income (loss) applicable to common stock	\$	101,659	\$ -	48,145	\$	43,157	\$	21,478	\$	(15,538)
Basic earnings (loss) per share ⁽¹⁾ :										
Before cumulative effect of accounting change	\$	0.67	\$	0.43	\$	0.35	\$	0.18	\$	(0. 14)
Cumulative effect of accounting change				(0.07)						
Basic earnings (loss) per share	\$	0.67	\$	0.36	\$	0,35	\$	0,18	\$	(0.14)
Diluted earnings (loss) per share ⁽¹⁾ :										
Before cumulative effect of accounting change	\$	0,59	\$	0.36	\$	0.29	\$	0.15	\$	(0. 14)
Cumulative effect of accounting change				(0.06)						
Diluted earnings (loss) per share	\$	0.59	\$	0.30	\$	0.29	\$	0,15	\$	(0.14)
Shares used in calculation of earnings (loss) per si	hare	:								
Basic		150,756	1	34,880	נ	.24,146	1	19,028		112,434
Diluted		181,481	1	59 ,3 10	נ	51,287	1	40,262	1	112,434
					De	cember 31,				
(In thousands)		2001		2000		1999		1998		1997
Consolidated Balance Sheets Data:										
Cash, cash equivalents and securities										
available-for-sale	\$	866,607	\$7	50,526	\$ 2	246,286	\$	73,502	3	69,657
Total assets	1	,141,216	8	56,406	2	507,074	1	25,273		106,013
Notes payable, less current portion		135,977	1	28,888	L	.22,910		2,095		3,886
Retained earnings (accumulated deficit)		115,086		13,427		(34,718)	(77,875)		(99,353)
Total stockholders' equity	\$	956,479	\$6	94,619		59,978	\$1	06,428		80,679

(1) Earnings (loss) per share for years ended December 31, 2000, 1999, 1998 and 1997 have been restated to reflect our three-for-one stock split effected by way of a stock dividend in January 2001.

www.idecpharm.com

corporate information

BOARD OF DIRECTORS

William H. Rastetter, Ph.D. Chairman and Chief Executive Officer, IDEC Pharmaceuticals Corporation

Herbert W. Boyer, Ph.D. Co-founder of Genentech, Inc., and current Genentech board member

Charles C. Edwards, M.D. Former President and CEO, Scripps Clinic and Research Foundation

Alan Burnett Glassberg, M.D. Associate Director, University of California, San Francisco Cancer Center; Director, Mount Zion Medical Center

Kazuhiro Hashimoto President, Zenyaku Kogyo Co., Ltd.

Franklin P. Johnson, Jr. General Partner, Asset Management Partners

Robert W. Pangia Investment Banker

Bruce R. Ross Former President, Bristol Myers Squibb U.S. Pharmaceutical Group; Currently President, CancerRx

The Honorable Lynn Schenk Lawyer, Chief of Staff to the Governor of California and Former U.S. Congresswoman

William D. Young Chairman of the Board and Chief Executive Officer, ViroLogic, Inc.

EXECUTIVE COMMITTEE

William H. Rastetter, Ph.D. Chairman and Chief Executive Officer

William R. Rohn President and Chief Operating Officer

Paul C. Grint, M.D. Chief Medical Officer

Nabil Hanna, Ph.D. Chief Scientific Officer

Phillip M. Schneider Chief Financial Officer

Wolfgang Berthold, Ph.D. Senior Vice President, Biopharmaceutical Sciences

John M. Dunn Senior Vice President, Legal and Compliance, and General Counsel

Connie L. Matsui Senior Vice President, Planning and Resource Development

David F. Broad, Ph.D. Vice President, Biological Bulk Manufacturing

John Leonard, Ph.D. Vice President, Product Development Edward M. Rodriguez Vice President, Finance and Controller

Christine A. White, M.D. Vice President, Medical Affairs

Michael E. Wiebe, Ph.D. Vice President, Quality

Mark Wiggins Vice President, Marketing and Business Development

SCIENTIFIC/CLINICAL ADVISORY BOARD

James P. Allison, Ph.D. Director, Cancer Research Laboratory; Professor of Immunology, Howard Hughes Medical Institute Research Laboratories, University of California, Berkeley

Fred R. Appelbaum, M.D. Director, Division of Clinical Research, Fred Hutchinson Cancer Research Center; Professor of Medicine, University of Washington, Seattle

Jeffrey Bluestone, Ph.D. Professor, Director, Ben May Institute for Cancer Research, Chicago

George P. Canellos, M.D. William Rosenberg Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, Boston

Alice B. Gottlieb, M.D., Ph.D. W.H. Conzen Chair in Clinical Pharmacology, Director of the Clinical Research Center and Professor of Medicine, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick

Antonio J. Grillo-López, M.D. Chief Medical Officer, Emeritus, IDEC Pharmaceuticals Corporation

Norman R. Klinman, M.D., Ph.D. Professor of Immunology, Department of Immunology, Scripps Clinic and Research Foundation, San Diego

Albert F. Lo Buglio, M.D. Director, Comprehensive Cancer Center, Evaline B. Spenser Professor of Oncology, Associate Dean for Research, School of Medicine, University of Alabama, Birmingham

Sherie L. Morrison, Ph.D. Chairman and Professor, Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles

Michelle A. Petri, M.D., MPH Associate Professor, Johns Hopkins Hospital, Department of Rheumatology, Baltimore

David Wofsy, Ph.D. Professor of Medicine and Microbiology; Chief, Rheumatology/Immunology, Veterans Administration Medical Center, University of California, San Francisco

CORPORATE HEADQUARTERS

IDEC Pharmaceuticals Corporation and Subsidiary

3030 Callan Road San Diego, CA 92121 Telephone: 858-431-8500 Facsimile: 858-431-8870 http://www.idecpharm.com

SUBSIDIARY

IDEC Seiyaku Contact: Michio Nishida Representative Director 8F Kyodo Bldg. (Shin-Kyobashi) 4-2-2 Hatchobori, Chuo-ku Tokyo 104-0032 Japan Telephone: 03-3552-1721 Facsimile: 03-3552-1810 (Chigasaki) Telephone: 0467-54-8195 Facsimile: 0467-54-1344

GENERAL COUNSEL

Pillsbury Madison & Sutro LLP San Diego, California

INDEPENDENT AUDITORS

KPMG, LLP San Diego, California

TRANSFER AGENT AND REGISTRAR

Mellon Investor Services, LLP Stock Transfer Department 400 South Hope Street Fourth Floor Los Angeles, California 90071 Telephone: 800-522-6645 http://www.melloninvestor.com

For change of address, lost stock certificates and other stock certificate-related inquiries, please write to the above address.

ANNUAL MEETING

The annual meeting of stockholders is scheduled to be held on Thursday, May 23, 2002 at 1:00 p.m. at Hilton La Jolla Torrey Pines, 10950 North Torrey Pines Road, La Jolla, California 92037.

FORM 10-K ANNUAL REPORT

A copy of the company's annual report on Form 10-K, as filed with the Securities Exchange Commission, is available without charge upon request to: Investor Relations IDEC Pharmaceuticals 3030 Callan Road San Diego, California 92121 Telephone 858-431-8656

IDEC Pharmaceuticals[®], PRIMATIZED[®] and Rituxan[®] are registered U.S. trademarks of the company. Zevalin[™] and PROVAX[™] are trademarks of the company.

© Copyright 2002 IDEC Pharmaceuticals.

31, 33);

15,

13,

IDEC Pharmaceuticals is a leader in the development of targeted immunotherapies for cancer and autoimmune diseases. The company's products act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient's blood or lymphatic system.

CORE VALUES OF IDEC PHARMACEUTICALS CORPORATION

Creation of New Standards of Care: IDEC Pharmaceuticals is driven by opportunities to discover, develop, manufacture and support the commercial applications of innovative, value-added therapeutic agents which establish new standards of care in the management of selected cancers and autoimmune and inflammatory diseases.

Trust, Honesty, Integrity, Quality: Our personal and corporate actions are founded in trust, honesty and integrity. Our products meet the highest quality standards.

Team as a Source of Strength: We embrace the team as the source of achievement, momentum and value creation. We recognize that the most effective teams draw strength from diverse groups and from diverse levels throughout the corporation.

Zeal and Commitment: Extraordinary teams and extraordinary products come from our zeal, and from our commitment to corporate objectives and to our constituencies: patients, caregivers, shareholders and employees.

Growth, Transformation and Renewal: Consistent with our Core Values, we as individuals and as a corporation are committed to creative and constructive growth, transformation and renewal as a source of innovation and vitality.

